


**CUMULATIVE INDEX**  
**VOLUME 10-12**  
**MARCH, 1967-DECEMBER, 1969**



# THREE-YEAR CUMULATIVE INDEX VOLUMES 10-12 (1967-1969)

- Abdominal scanning, ultrasonic, 12:356-357  
 aminopterin-induced, 11:420  
 aseptic, 11:557-559  
 diamine oxidase levels in plasma and, 11:1087-1090  
 habitual  
   etiology of, 12:921-924  
   incidence and prognosis of, 12:921  
   treatment of, 12:924-926  
 in hemoglobinopathies, 12:38, 67, 117, 129, 136, 142, 153-155  
 hormonal cytology in, 11:1117-1118, 1134-1136  
 therapeutic  
   in heart disease, 11:918-919, 979, 1017, 1049-1050, 1061  
   in renal disease, 11:595-596  
 Abruptio placentae, 11:601, 1001-1002, 1149  
   cesarean hysterectomy in, 12:620, 640, 671-672  
 Acetylcholine effect on labor, 11:46-49  
 Acid aspiration syndrome, in anesthesia, 11:1002-1008  
 Acid-base balance  
   fetal, 11:1187-1188  
   labor affecting, 11:168-190  
   fetal-maternal relationships and, 11:175  
   maternal, 11:945, 1171-1172  
   alkaline substances and, 11:121-122  
   anesthesia and mode of delivery, 11:122-123  
   glucose infusion and, 11:121  
   in labor, 11:113-115, 121  
   oxytocin effect and, 11:122  
   parity and, 11:119-121  
   in pregnancy, 11:110-113, 562, 564-565  
   respiratory component and, 11:118-119  
   at time of delivery, 11:114  
 non-pregnant, 11:110  
 Actinomycin D therapy, 10:319-320, 331, 332, 336-338  
 Addison's disease, 12:782  
   in old age, 10:649  
   pregnancy and, 10:98-100  
 Adenocarcinoma of cervix, 10:962-963  
 Adenohypophysis, *see* Pituitary—anterior  
 Adenomyosis, dysmenorrhea with, 12:721  
 Adhesions, ovarian, 12:897  
 Adolescence  
   autoeroticism in, 11:767  
   behavior patterns in, 11:760  
   educational and emotional preparation for, 11:757-758, 763-765  
   growth patterns in, 11:760-763  
   physical change, adaptation to, 11:758-763  
   role definition, 11:758  
   sexual feelings in, 11:766  
   *See also* Puberty  
 Adrenal glands  
   conversion of progesterone to corticosteroids, 10:53  
   cortex  
     cortical function tests in hirsutism, 12:817  
     disorders of, and primary amenorrhea, 11:867-871  
     normal biosynthesis of cortisol and androgens in, 11:819-822, 865-866  
   corticoid therapy in breast cancer, 11:410  
   in female over 65, 10:468-469  
   fetal development of, 10:52-55  
     hyperplasia  
       acquired, 11:819  
       congenital, *see* Congenital adrenal hyperplasia  
   menstrual disorders with dysfunction of, 12:771-783  
 Adrenogenital syndrome, *see* Congenital adrenal hyperplasia

Volume 10, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

Volume 11, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

Volume 12, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- Agglutination-inhibition tests, for  
human gonadotropins,  
10:121-122, 305-307
- Aging  
cancer and, 10:498-518  
endocrinology, 10:466-478  
gynecologic problems of, 10:540-541  
medical complications in, surgery,  
10:481-487  
premature, estrogen therapy for,  
10:477-478  
psychiatric illness and, 10:532-543  
reproductive organs, 10:454-465
- Air embolism in pregnancy, 11:997-998
- Aldosterone  
excretion of, 10:92-94, 95-97  
mechanism of action, 10:88  
in pregnancy, finding in plasma pro-  
tein, 10:93-94  
sodium retention and, 11:465-466,  
468, 568-570
- Aldosteronism, primary, and pregnancy,  
10:100-101
- Alkaline phosphatase in maternal  
plasma, 11:1098-1101
- Alkylating agents, in cancer, 11:334-  
337, 405-406
- Altitude, affecting placental gas trans-  
fer, 11:1170, 1178
- Amenorrhea, 12:693-707, 901  
hypothalamic, 10:365  
in hypothyroidism, 12:756-758  
oral contraceptive use and, 11:648-  
649, 722; 12:796
- primary  
genetic causes of, 11:835-852  
in puberty, 11:854-877  
psychogenic, 11:863  
psychologic, 12:793-794  
secondary, 12:700-701, 737-738
- Amethropin therapy in gynecologic  
cancer, 11:337-338
- Amino acids in fetal plasma, 11:1191-  
1192
- Aminocentesis, 11:1195-1197
- Amnioscopy, 12:527-532  
complications of, 12:531-532  
meconium detection in, 12:529-531
- Amniotic fluid, 11:1193-1202  
alterations in composition, 11:1194-  
1195  
analyses of, 11:1197-1199  
bilirubin in, 11:1195  
creatinine in, 11:1195  
development of, 11:1193-1194  
embolism, 11:1000-1001  
erythropoietin in, 11:1200  
estriol in, 11:1110, 1200-1201  
interpretation of findings, 11:1198  
protein in, 11:1199-1200
- Ampicillin therapy in pregnancy bac-  
teriuria, 11:545-546
- Amyloidosis  
bladder in, 10:208  
in pregnancy, 11:475
- Analgesics in dysmenorrhea, 12:714
- Androgens, 12:715, 771-774, 802-810  
deficiency in female, and CAH,  
11:818-819  
in estriol production, 10:66-68  
female virilization effect, 10:30-32  
natural, 10:63-64  
normal biosynthesis of, 11:819-822  
in peripheral plasma, 10:30-32  
*See also specific androgens*
- Androstenedione  
in peripheral plasma, 10:32-33  
placental perfusion of, 10:62
- Androsterone in hirsutism, 12:822
- Anemia  
diagnosis with radioisotopes, 12:420  
in elderly surgical patient, 10:485  
in heart disease with pregnancy,  
11:914, 1020  
in hemoglobinopathies, 12:140, 146,  
152  
iron deficiency, 12:34, 117, 129  
sickle cell, 12:33-34, 50, 124
- Anencephaly, estriol excretion in,  
10:68-69
- Anesthesia in pregnancy  
agents affecting newborn, 12:600,  
601, 603-604, 612-613  
in cardiac disease, 11:920-921, 940-  
966  
acid-base balance and, 11:945  
agents for, 11:948-951  
in arrhythmias, 11:965  
aspiration of gastric contents and,  
11:1002-1008  
for cesarean section, 11:961-962  
circulatory changes and, 11:943-  
945  
in congenital heart disease, 11:964  
in congestive heart failure, 11:963  
in coronary artery disease, 11:965  
in hypertensive heart disease,  
11:964-965  
inhalation techniques, 11:950, 957  
in labor, 11:952-953  
narcotics in, 11:948, 954-955  
psychologic effects of, 11:946  
psychologic techniques, 11:958  
regional techniques, 11:948, 955-  
957

- respiratory changes and, 11:941-943  
 in rheumatic heart disease, 11:962-963  
 sedatives in, 11:948, 954  
 for vaginal delivery, 11:958-961  
 in cesarean hysterectomy, 12:590-617  
 drug interactions in, 12:616-617  
 epidural block, 12:606-612  
 hypertension in and hypotension in, 12:615-616  
 hypnotics and narcotics in, 12:595, 600-601  
 inhalation agents, 12:593-594, 596-600  
 muscle relaxants, 12:601-602  
 nitrous oxide, placental transfer of, 11:1172-1175  
 psychosedatives in, 12:595-596  
 regional techniques, 12:602-612  
 spinal, 12:604-606, 610-612  
 techniques of, 12:593-596  
 Angiography in gynecologic cancer, 12:387-394  
   in ovarian malignancy, 12:393-394  
   in uterine malignancy, 12:391-393  
 Angiotensin II, and pressor responses, 10:94  
 Anorexia nervosa, and primary amenorrhea, 11:863-864; 12:793  
 Anovulation, 10:392-393; 12:897  
 Antibacterial drugs  
   causing urinary tract infections, 10:169  
   for urinary tract infections, 10:176-180, 552, 524  
 Antibiotics  
   in cancer chemotherapy, 11:335, 337  
   in pelvic infections, 12:219-237  
     for anaerobic organisms, 12:227-228  
     in *Bacteroides* infections, 12:228  
     combinations of, 12:223-224  
     in enterococcal infections, 12:226-227  
     fungal infections and, 12:235-236  
     in gonorrhea, 12:229, 230  
     for gram-negative enteric organisms, 12:228-229  
     in mycoplasma infections, 12:229  
     in postoperative infections, 12:279-280  
     in renal disease, 12:224  
     in salpingitis, acute, 12:230-231  
     in staphylococcal infections, 12:226  
     in streptococcal infections, 12:227  
     in thrombophlebitis, septic, 12:231, 244  
     in tuberculosis, genital, 12:233  
     in tubo-ovarian abscess, 12:257  
     in wound infections, 12:233-234  
   in rheumatic heart disease in pregnancy, 11:1019-1020  
   in venous thromboembolic disease, 11:271  
 Anticoagulants in thromboembolism, 11:237-243, 264-265, 271-275  
   postoperative, 11:281-288  
   in pregnancy, 11:292-298, 304-306, 918, 995-996  
 Antidiuretic (ADH), uterine effect, 11:15, 46-49  
 Antihemophilic globulin (Factor VIII), 11:209, 217-218  
 Antihypertensive therapy in acute renal failure, 11:563-564  
 Antimetabolites in cancer, 11:335-339, 406-409  
 Anxiety  
   in pregnancy with heart disease, 11:913-914, 946, 1020  
   in women over 65, 10:533-534  
 Aortic coarctation in pregnancy, 11:1054-1056  
 Apgar scores  
   fetal pH values and, 11:182-185  
   of infants of cardiac patients, 11:1035  
 Appendicitis, acute, in elderly female, 10:549-551  
 Appendix, mucocoele of, 10:553-554  
 Arrhythmias, cardiac  
   in elderly surgical patient, 10:483-484  
   in pregnancy, 11:921-922, 969  
   anesthesia in, 11:965  
 Arteries  
   air embolism in pregnancy, 11:998  
   blood flow in, 11:70-71

**Volume 10**, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

**Volume 11**, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

**Volume 12**, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- changes in pregnancy, 11:974-975  
 endometrial spiral, 11:78-79, 88, 91-92  
 in uteroplacental circulation, 11:79-83
- Arteriography, *see* Angiography
- Ascites in ovarian carcinoma, 12:960-961
- Aspiration of gastric contents, in anesthesia, 11:1002-1008
- Atrial arrhythmias in pregnancy, 11:921
- Atrial septal defect in pregnancy, 11:1052, 1053
- Atropine, uterine effect, 11:64
- Au<sup>198</sup> test, 12:896
- Auscultatory fetal monitoring, ultrasonic, 11:1154-1164
- Autoeroticism in pubescent female, 11:767
- Autogenous vaccines in treatment of pseudomyxoma peritonei, 12:955-957
- Azathiopurine therapy in pregnancy, 11:423
- Azospemia and infertility, 12:853
- Backache in chronic urinary infection, 10:167
- Bacteremia in rheumatic heart disease in pregnancy, 11:1023
- Bacteriuria  
   asymptomatic, 10:166, 168, 171-173  
   nonantibiotic antibacterial drug therapy, 10:182  
   in pregnancy, 10:169; 11:533, 539-540  
     chemical screening test for, 11:534  
     fetal loss and, 11:543  
     hypertension and, 11:544  
     preeclampsia and, 11:533, 543-544  
     prematurity and, 11:540-543  
     prognosis in, 11:545  
     pyelographic abnormalities in, 11:536-537  
     pyelonephritis, 11:533, 538-539  
     renal disease underlying, 11:536, 540  
     renal function defects in, 11:536  
     serum antibody studies in, 11:536  
     spontaneous disappearance after delivery, 11:536  
     symptomatic infection and, 11:538  
     toxemia and, 10:174-175  
     urine sample in, 11:534
- Barbiturates  
   in obstetrics, 12:595, 600-601  
   in pregnancy with heart disease, 11:948, 954
- uterine effect, 11:64
- Barium enema in diverticulitis, 10:546
- Bartholin's gland and vulvar cancer, 10:646, 648-649
- Basal body temperature  
   infertility and, 12:860, 864, 898  
   ovulation and, 10:382
- Bicarbonate levels, maternal, affecting fetus, 11:1171
- Bilirubin in amniotic fluid, 11:1195
- Biochemical indices of fetal condition, 11:1182-1202
- Biopsy  
   hepatic, 11:494-495, 496-497, 498-501  
   punch, 10:872  
   renal, 11:437-485, 522-523, 600  
     contraindications to, 11:475  
     evaluation of, 11:508-509  
     evaluation of patient, 11:474-475  
     immunofluorescent studies of, 11:522-531  
     indications for, 11:475  
     in pregnancy, 11:473-485  
     technique of, 11:474, 523  
     in urinary tract infections, 10:176, 523  
   wedge, at cesarean section, 11:474
- See also* Conization, cervical
- Birth rate in U.S., and oral contraceptive use, 11:749-751
- Bittner virus, 10:884
- Bladder  
   amyloidosis affecting, 10:192  
   atony of, postoperative, 10:192  
   bacteria from urethra in, 10:195  
   catheterization after gynecologic surgery, 10:192-195  
   connective tissue changes in interstitial cystitis, 10:186-187  
   dissection of, 10:206-207, 209  
   diverticular of, 10:210  
   drainage of, 10:195-198  
   endometriosis of, 10:208  
   foreign bodies in, 10:207-208, 209  
   inflammatory diseases of, 10:208  
   injury to in cesarean hysterectomy, 12:644, 650, 669-670  
   irrigation of, postoperative, 10:197-198  
   neoplasms of, 10:206, 207  
   postoperative care, 10:192-199  
   pseudotumors of, 10:206-210  
   rectosigmoid, for urinary diversion, 10:221-225  
   resection in interstitial cystitis, 10:189, 190

- vesicovaginal fistula, 10:547-548, 590-591
- Bleeding**  
breakthrough, and oral contraceptives, 11:720-722  
postpartum, curettage for, 10:276, 278, 280, 281
- Blood**  
changes in  
from oral contraceptives, 11:672-673  
during ovulation, 10:386  
coagulation of, *see* Coagulation  
enzyme levels in pregnancy, 11:1081-1104  
fetal studies, 11:1184-1193  
in acid-base state, 11:1187-1188  
amino acids and lipids, 11:1191-1192  
constituents of, 11:1190  
glucose, 11:1190  
hematocrit, 11:1190  
hemoglobin, 11:1191  
hormones, 11:1192  
immunoglobulins, 11:1192  
lactate and pyruvate, 11:1189  
oxygen tension, 11:1188-1189  
technique of sampling, 11:1184-1187  
micro sampling techniques, 11:169-1190  
flow studies, *see* Circulation  
micro sampling techniques, 11:169-171  
platelets in, *see* Platelets  
sex steroids in, 10:29-38
- Blood pressure**  
in labor, 11:935  
ovulatory changes, 10:385  
in pregnancy, 11:928, 933-934  
supine hypotensive syndrome, 11:932-933, 944  
*See also* Hypertension
- Blood vessels, uterine, 11:23-24**  
*See also* Arteries; Vascular conditions; Veins
- Blood volume**  
placental, in labor, 11:934  
in pregnancy, 11:928-929, 931-932, 944, 1012-1013  
radioisotope studies of, 12:419-420
- Bradycardia, fetal, *see* Fetus—heart rate of**
- Brain**  
metastases to, ultrasonic studies of, 12:365-367  
scanning of, 12:415-417
- Breast**  
cancer of, *see* Cancer—breast  
development in pregnancy, 10:137-138  
development in puberty, 11:761, 775  
effect of oral contraceptives on, 11:661-663
- Busulfan therapy in pregnancy, 11:421-422**
- CAH, *See* Congenital adrenal hyperplasia**
- Calcium**  
deprivation of, and uterine contractions, 11:23  
Factor IV, in blood, 11:209
- Calculi**  
renal, 10:525-526  
urinary, and infection, 10:175, 525-526
- Cancer**  
in aged, 10:498-517, 551-553  
Bartholin's gland, 10:646, 648-649  
breast  
advanced, 11:410-411, 412  
chemotherapy, 11:401-413  
combination therapy for, 11:409  
local disease management, 11:411, 413  
cervical, 10:559, 567-598, 881-1015  
adhesions and, 10:590  
in aged, 10:515-516  
associated diseases, 10:933-934  
cellular differentiation, 10:908-914  
classification, 10:909, 911-913  
epithelial alterations with, 10:907-908  
experimental, 10:887-891  
fistulas and, 10:590-591  
genesis of, 10:883-918  
in Jews, 10:893  
in situ, *see* Carcinoma in situ  
invasive, 10:567-598, 881-1015

**Volume 10**, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

**Volume 11**, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

**Volume 12**, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- ovarian cancer and, 10:589-590
- pelvic relaxation and, 10:585-588
- radiation therapy, *see* Radiation therapy
- surgery for, 10:575, 591-593, 911-957
- tubal disease and, 10:588-589
- vaginal extension of, 10:580, 582, 585
- chemotherapy, 11:334-353
  - application of, 11:340-344
  - in breast cancer, 11:401-413
  - cell targets of, 11:336
  - clinical experimentation in, 11:352-353
  - complications prevented, 11:347-349
  - curative, 11:343
  - cytotoxic drugs, 11:334-340
  - drug administration, 11:344-345
  - drug classification, 11:334-335
  - drug dosage, 11:345-347
  - duration of therapy, 11:347
  - mode of action, 11:335-337
  - in ovarian cancer, 11:354-366, 382-399
  - palliative, 11:342-343
  - postoperative, 11:344
  - prophylactic, 11:343
  - radiotherapy with, 11:343
  - regional, in squamous cell carcinoma, 11:367-380
  - resistance to, 11:339-340
  - response to, 11:349-352
  - in squamous cell carcinoma, 11:367-380
  - toxicity of, 11:339
  - tumor resistance, 11:339-340
  - in vaginal carcinoma, 10:662-663
  - of colon and rectum, in aged, 10:551-553
- endometrial, 10:625-639; 11:439, 441-452; 12:940-941
  - in aged, 10:508-511
  - metastatic, 11:452-455
- oral contraceptives and, 11:679-680
- ovarian, 10:599-623
  - in aged, 10:511-515
  - bilateral, in young patient, 10:615
  - cervical cancer and, 10:589-590
  - chemotherapy, 11:354-366, 382-399
  - over-all management of, 11:364
  - pseudoprecocious puberty and, 11:805-809
  - radiotherapy in, 11:365, 387
  - stage grouping of, 11:392-394
  - pelvic, 10:566, 930-933
  - squamous cell, *see* Squamous cell carcinoma
  - urethral, 10:230, 521
  - uterine
    - computerized data collection in, 10:1003-1014
    - secondary, 10:559
    - therapy in, 11:440-441
  - vaginal, 10:655-663
  - vulvar, 10:641-653
    - age distribution, 10:503-508
    - in aged, 10:503-508
    - in Bartholin's gland, 10:646, 648-649
    - intraepithelial, 10:643-646
    - pelvic exenteration for, 10:643-646
    - secondary primary malignancy with, 10:650-652
- See also* Tumors
- Candidiasis
  - gentian violet in, 12:209
  - in antibiotic therapy, 12:235-236
  - nystatin in, 12:208-209
  - oral contraceptives affecting, 12:207-208
  - vaginitis, 12:204-210
- Carbocaine in obstetrics, 12:603
- Carcinoma in situ, 10:745-879
  - causative factors, 10:853
  - cervical, and herpetic infection, 12:167
  - cytology of, 10:792-795, 896-899
  - first diagnosis of, 10:755
  - histology of, 10:799, 803
  - hysterectomy with vaginal cuff, 10:858-867
  - in pregnancy, 10:856-858, 870-876
  - recurrence rate, 10:853
  - surgical treatment of, 10:852-867
  - See also* Conization, cervical; Ovary—carcinoma of
- Cardiac disease
  - arrhythmias, *see* Arrhythmias
  - in pregnancy, 11:910-922
  - See also* Heart disease in pregnancy
- Cardiac output in pregnancy, 11:925-934, 943-944, 1011-1012
  - cardiac catheterization in, 11:926
  - dye catheterization in, 11:926
  - in labor, 11:934-936
  - myocardial reserve response, 11:929
  - in normal females, 11:924-925
  - peripheral resistance and, 11:928
  - placenta affecting, 11:930-931
  - plasma volume studies, 11:928-929, 931-932, 944, 1012-1013
  - pressure studies, 11:928



- pulmonary vascular pressures,  
11:928, 933-934
- right heart changes, 11:928, 933-934
- supine hypotensive syndrome and,  
11:932-933, 944
- ventricular work, 11:929
- Cardiac pool scanning, 12:417-419
- Cardiovascular disease  
in elderly surgical patient, 10:481-484
- endometrial cancer and, 10:628
- Cardiovascular hemodynamics in pregnancy, *see* Cardiac output
- Cardiovascular signs arising during pregnancy, 11:968-977
- heart rate and rhythm, 11:969
- heart sounds, 11:969
- mammary souffle, 11:973-974
- murmurs, 11:970-974
- peripheral vascular system, 11:974-975
- precordial impulses, 11:968
- venous hum, 11:972-973
- Caruncle, urethral, 10:228-231
- Catheter, 10:192-193, 195, 198
- Catheterization  
cardiac, in pregnancy, 11:926
- urinary  
after gynecologic surgery, 10:192-195, 198-199
- urinary tract infections and,  
10:169, 192, 195-198
- Cellular Volume Counter, 12:322-324
- Cellulitis, pelvic  
ligeneous, 12:247-249
- postoperative, 12:266, 277
- Central nervous system (CNS)  
disorders of  
primary amenorrhea and, 11:861-863; 12:694-695, 701
- pseudoprecocious puberty and,  
11:799-801
- effect of oral contraceptives on,  
11:672, 724
- puberty and, 11:784-785
- sexual differentiation of, 12:796-797
- Cephalosporins, in pelvic infections,  
12:221
- Cervical conditions, *see* Cervix uteri;  
Uterus
- Cervicovaginal smear, 10:786-799
- Cervix uteri  
in aging female, 10:459-460
- cancer of, *see* Cancer, cervical
- congenital anomalies, 11:851
- dysplasia of, 10:749-751, 893-896
- progression to CIN, 10:769-772
- versus carcinoma in situ, 10:794, 802-803
- erosion of, 10:814
- incompetent os, and diamine oxidase levels in plasma, 11:1090-1091
- infertility and, 12:859, 881-886
- treatment, 12:913-914
- intraepithelial neoplasia (CIN)  
colpomicrosocopy in, 10:751, 753-755, 758, 759-760
- colposcopy, and postpartum injury,  
10:760-762
- differentiated from carcinoma in situ, 10:756
- electron microscopy in, 10:766-768
- exfoliative cytology in, 10:751-753
- lesion growth and cell changes,  
10:781-782
- mitotic accidents, 10:774-776
- morphology of, 10:757-759
- natural history of, 10:748-784
- portio involvement and, 10:762-763
- progression of dysplasia to CIN,  
10:769-772
- radioactive thymidine and mitotic rate, 10:773-774
- results of, 10:800-806
- spread of, 10:762-769
- tissue culture studies, 10:768-769
- mucus, 10:384
- postpartum injury, 10:760-762
- secondary tumors of, 10:559
- stromal infiltration, 10:899-904
- Cesarean section  
in Addison's disease patients, 10:99-100
- in cardiac patients, anesthesia for,  
11:961-962
- hysterectomy and, *see* Hysterectomy
- postoperative infection and, 12:272-273

Volume 10, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

Volume 11, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

Volume 12, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- Chemotherapy  
  in cancer, *see* Cancer—chemotherapy  
  in ovarian carcinoma, 12:990–991, 1006–1008  
    changing alkylating agents and, 12:1013–1014, 1015  
    external radiation therapy and, 12:1013  
    longevity and, 12:1010–1012  
    management of, 12:1014–1015  
    review of literature about, 12:1008–1010  
    toxic effects of, 12:1012–1013  
  in trophoblastic disease, 10:267, 330–340
- Chiari-Frommel syndrome, 12:702, 794
- Children, ovarian tumors in, 12:931–932
- Chlorambucil therapy in gynecologic cancer, 11:346  
  in pregnancy, 11:422
- Chloramphenicol in pelvic infections, 12:221, 280
- Chlormadinone acetate, 11:628, 633  
  antifertility effect, 11:637–638  
  relationship of dose to ovulation suppression, 11:634, 648
- Chloroform in obstetrics, 12:597
- Cholesterol  
  desmolase deficiency, and CAH, 11:824  
  metabolism, 12:772
- Chorioadenoma destruens, *see* Trophoblastic disease
- Choriocarcinoma, 10:267, 269  
  differentiation from early pregnancy, 10:285, 286, 288  
  hydatidiform mole with, 10:270, 313  
  metastases, 10:283, 296–298  
  necrotic, 10:267, 277  
  nodules of, 10:280–281  
  *See also* Trophoblastic disease  
  pregnancy following, 11:421
- Chorionic gonadotropin, *see* Gonadotropins
- Chorionic growth hormone-prolactin (CGP), 10:133, 140  
  *See also* Lactogen, human placental
- Chromosomes, 12:435–456  
  aberrations in, 12:435–440  
    amenorrhea and, 12:695–700  
    numerical, 12:436–438  
    structural, 12:438–440  
  aneuploidy, 12:437–438  
  karyotype, 12:436  
  normal, 12:435  
  in ovarian malignancy, 12:445–447  
  polyploidy, 12:436
- technic of preparations, 12:447–451  
  in trophoblastic diseases, 12:447  
  in uterine malignancy, 12:441–445
- Circulation  
  arterial physiology of, 11:70–71  
  changes in pregnancy, 11:924–937, 943–944, 1011–1013  
  extracorporeal, in pregnant cardiac patients, 11:917–918  
  hepatic, 11:487  
    in pregnancy, 11:461–462  
  pulmonary, in cor pulmonale, 11:992–1008  
  renal, 11:487  
    in pregnancy, 11:461–462  
  uterine  
    in labor, 11:96–108  
    in pregnancy, 11:69–76  
  uteroplacental, 11:71–72  
    *See also* Uteroplacental circulation
- Citanest in obstetrics, 12:603
- Clomid, *see* Clomiphene citrate
- Clomiphene citrate, 10:74, 77–81  
  biologic effects, 10:390–391  
  dosage, 10:394  
  effect on ovulatory defects, 10:390–399  
  gonadotropin effect, 10:78, 80–81  
  -induced pregnancies, 10:397–398  
  ovarian effect, 10:79, 80–81  
  for ovulation induction, 11:649, 671  
  selection of patients, 10:392–394  
  side-effects, 10:393, 394–396
- CO<sub>2</sub> test, 12:891–893
- Coagulation  
  alterations in, 11:261–262  
  antithrombins, 11:219  
  classic theory of, 11:207–208  
  clinical aspects of, 11:222–228  
  clot stability, fibrinase and, 11:218–219  
  clotting factors, 11:201–203, 207–219  
    control of, in vivo, 11:221–222  
    evaluation of, 11:223–226  
    extrinsic system, 11:215–216  
    hypercoagulability of, 11:203–205  
    intrinsic reactions, 11:216–222  
    nomenclature of, 11:209–211  
    in pregnancy, 11:234  
  oral contraceptives and, 11:675–676  
  plasma clotting factors, 11:220–221
- Coarctation of aorta in pregnancy, 11:1054–1056
- Cobalt-60 moving strip technique in radiotherapy in ovarian carcinoma, 12:994–997
- Cobalt teletherapy, in advanced ovarian cancer, 11:390–391

- Coitus interruptus, 11:684
- Colcemide therapy, in pregnancy, 11:423
- Colistin in pelvic infections, 12:222
- Colon  
cancer of, in elderly, 10:551-553  
diverticulitis of, 10:545-549  
diverticulosis of, 10:544-545  
use of, in urinary diversion, 10:217-226
- Colpomicroscopy, 10:808-809  
for detection of CIN, 10:751, 753-755, 758, 759
- Colposcopy, 10:808-836, 872-873  
in diagnosis, 10:817-828  
methods of, 10:828-835  
postpartum injury of cervix and, 10:760-762  
principles of, 10:810-817
- Colpotomy in ovarian carcinoma, 12:961-962
- Complement fixation tests for human gonadotropins, 10:121
- Compound F, *see* Cortisol
- Computer data collection, in management of cervical cancer, 10:1003-1014
- Condylomata acuminata, 10:233; 12:170-172
- Congenital adrenal hyperplasia (CAH), 10:31, 100; 12:774-779  
with Addison's disease, 11:818  
amenorrhea in, 12:695-696  
with androgen deficiency, 11:818-819  
determination of sex, 11:825-828  
diagnosis of, 11:825-828  
drug therapy for, 11:828-830  
female syndrome, 11:816  
genetics of, 11:831-832  
with hypertension, 11:818  
with incomplete masculinization, 11:818  
male syndrome, 11:817  
maternal, and subsequent pregnancy, 11:831  
mild or latent, 11:868-870  
pathogenesis, 11:819-825  
primary amenorrhea and, 11:837-840, 867-870  
surgical treatment of, 11:830-831
- Conization, cervical  
frozen section, 10:837-850  
hysterectomy following, 10:837, 838; 12:273-274  
in pregnancy, 10:856-858, 873-875  
technique, 10:838-840, 854-858
- Contraception, 10:681-683  
advice for cardiac patients, 11:1061-1062  
coitus interruptus, 11:684  
effect on future fertility, 11:688  
immunologic approach to, 11:630  
interference with transport of gametes or tubal secretions, 11:629  
intrauterine device (IUD), 11:627, 685  
mechanical methods of, disadvantages of, 11:684-685  
methods of, and comparative pregnancy rates, 11:670  
mode of action, attitude toward, 11:688-689  
oral contraceptives, *see* Oral contraceptives  
postcoital, 11:642, 671  
psychoneurotic attitude toward, 11:691-692  
responsibility for, 11:687-688  
suppression of spermatogenesis, 11:630
- Cor pulmonale in pregnancy, 11:992-1008  
from extraluminal pulmonary vascular obstruction, 11:1002-1008  
from intraluminal pulmonary vascular obstruction, 11:992-1002  
overloading of circulation and, 11:992
- Coronary artery disease  
atherosclerosis, and ovarian function in aging, 10:475-478  
in pregnancy, anesthesia in, 11:965
- Corpus luteum  
effect of aging on, 10:460-461  
evaluation of function, 10:393-394  
ovulation and formation of, 10:408  
progestogens from, 10:373

**Volume 10**, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

**Volume 11**, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

**Volume 12**, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- Corticosteroids  
 role in hirsutism, 12:811-812  
 therapy with  
   in hirsutism, 12:820-821  
   in pelvic infections, 12:247-251
- Cortisol  
 for CAH, 11:828-829  
 normal biosynthesis of, 11:819-822, 865-866  
 in pregnancy, 10:88-90, 95-97; 11:462, 465  
 secretion rate, determination of, 12:781
- Cortisone, for CAH, 11:828-829
- Coumarin drugs in thromboembolic disease, 11:273-274  
 in pregnancy, 11:294-297, 995-996
- Creatinine  
 in amniotic fluid, 11:1195  
 clearance studies, 12:427-428
- Culdoscopy, 12:484-502, 504-507, 508, 511, 512, 900  
 anesthesia in, 12:495  
 cinematography with, 12:493-495, 535-536  
 comparison with laparoscopy, 12:495, 525  
 complications of, 12:498-499  
 indications for, 12:498  
 for ovarian biopsy, 12:505-507  
 in ovarian carcinoma, 12:961-962  
 postoperative care, 12:492-493  
 procedures in, 12:490-497  
 recent advances in, 12:504-513  
 report of series, 12:499-502  
 with tubal perfusion, 12:897
- Cushing's disease, 12:780-782  
 in old age, 10:469  
 pregnancy and, 10:97-98  
 primary amenorrhea and, 11:870-871
- Cyanosis, maternal, affecting infant, 11:1058
- Cyclophosphamide therapy  
 in cervical cancer, 11:371  
 dosage, 11:346  
 mechanism of action, 11:383-384  
 natural resistance to, 11:340  
 in ovarian cancer, 11:356, 385-398  
 in pregnancy, 11:422  
 in squamous cell carcinoma, 11:370-371  
 toxicity, 11:384-385
- Cyclopropane anesthesia for cesarean section, 12:597
- Cyprane inhaler, 12:594
- Cyproterone in hirsutism, 12:822
- Cyst(s)  
 blind urachal, 10:214  
 gastrointestinal, 10:556  
 ovarian, from clomiphene therapy, 10:393, 395, 399  
 periurethral glands, 10:233-234
- Cystic ovaries, *see* Stein-Leventhal syndrome
- Cystic tumors, ultrasonic diagnosis of, 12:358-361
- Cystitis  
 in aged female, 10:522-523  
 bullous, 10:208  
 cystica, 10:208  
 cystoscopy in, 10:522-523  
 interstitial, 10:186-190  
 postoperative, from catheterization, 10:194
- Cystocele  
 in elderly female, 10:488, 495  
 after radiotherapy for cancer, 10:588  
 surgical repair, and stress incontinence, 10:490-491
- Cystography, excretory, in ureterocele, 10:157, 160
- Cystoscopy, in cystitis, 10:522-523
- Cytochemical techniques, and radiosensitivity studies, 12:343-344
- Cytologic screening, 12:303-333  
 automated systems for, 12:319-324  
 in carcinoma in situ, 12:305-306  
 classes of smears, 12:308  
 computerized record keeping and, 12:326-330  
 cytohistologic correlation in, 12:304-307  
 in dysplasia of cervix, mild, 12:305  
 in endometrial carcinoma, 12:310-311  
 follow-up studies, 12:325-326  
 in invasive carcinoma, 12:306-307  
 laboratory facilities for, 12:318-324  
 in leukoplakia, cervical, 12:304  
 malignancy, associated changes, 12:312  
 mass programs of, 12:324-331  
 in metaplasia, squamous, 12:304  
 methods of reporting in, 12:307-308  
 in ovarian carcinoma, 12:311  
 of prenatal patients, 12:313-316  
 self-obtained smears, 12:317-318
- Cytology  
 of cervical dysplasia and carcinoma in situ, 10:785-806  
 for detection of CIN, 10:751-753  
 for detection of ovulation, 10:381  
 vaginal, in pregnancy, 10:870-871; 11:1113-1118, 1121-1138  
 in abortions, 11:1117-1118, 1134-1136

- cell types defined, *11:1124*  
 collection and evaluation of smear,  
*11:1113-1114, 1122-1123*  
 cytolysis and, *11:1115-1116, 1128*  
 at end of pregnancy, *11:1118, 1130-1131*  
 in fetal death, *11:1136-1137*  
 in first trimester, *11:1126-1130*  
 hormone-tissue interaction,  
*11:1121-1122*  
 indices used in, *11:1124*  
 interpretation of findings, *11:1123-1125*  
 normal patterns, *11:1114-1115, 1125-1131*  
 postnatality patterns, *11:1134*  
 postpartum patterns, *11:1131-1133*  
 prognostic significance of,  
*11:1116-1117*  
 reactivity of smear to estrogens,  
*11:1116, 1137*  
 staining techniques, rapid,  
*11:1122-1123*  
 urocytogram, *11:1125*  
 vaginal flora affecting, *11:1116, 1125, 1130; 12:900*  
 Cytolysis in vaginal smears in pregnancy, *11:1115-1116, 1128*  
 Cytomegalovirus infection, cervical,  
*12:169-170*  
 Cytophotometric Field Analyzer (CYDAC), *12:320*  
 Cytoscreeners, need for, *12:318-319*  
 Cytoxan, *See Cyclophosphamide*  
 Dactinomycin therapy in gynecologic cancer, *11:346*  
 Dehydroepiandrosterone metabolism,  
*12:771-773*  
 Dehydroepiandrosterone sulfate, *10:63-66*  
 Dehydrogenase, hydroxysteroid, in adrenogenital syndrome,  
*12:778*  
 Deladroxate, monthly injection of,  
*11:629*  
 Delalutin in gynecologic cancer, *11:346, 371*  
 Delivery  
   blood loss in, *11:125*  
   and disappearance of bacteriuria,  
     *11:536*  
   general anesthetics in, *11:64-65*  
   in heart disease, *11:920*  
   time of, in maternal renal disease,  
     *11:601*  
   uterine activity in, *11:126-130*  
   *See also Labor*  
 Depo-Provera, injection of, *11:628-629*  
 Depression  
   oral contraceptives and, *11:672, 724*  
   in women over 65, *10:534, 538-539*  
 Dexamethasone  
   HCG test and, *12:1021-1022*  
   in hirsutism, *12:820*  
 Dextran in thromboembolic diseases,  
   *11:244-245, 274-275*  
   in pregnancy, *11:298*  
 Diabetes  
   in elderly surgical patient, *10:484*  
   latent, in pregnancy, *11:463-464, 513*  
   fetal effect, *11:572-573*  
   -like state, and oral contraceptives,  
     *11:673-674*  
   in pregnancy, and diamine oxidase  
     levels in plasma, *11:1092-1095, 1097*  
   primary amenorrhea and, *11:876, 877*  
   urinary tract infection and, *10:169, 175*  
 Diamine oxidase in maternal plasma,  
   *11:1081-1098*  
   assay procedure, *11:1082*  
   in assessing high-risk fetus, *11:1096-1097*  
   in diabetic patients, *11:1092-1095, 1097*  
   in diagnosis of pregnancy, *11:1087*  
   habitual abortion and, *11:1090*  
   incompetent os syndrome and,  
     *11:1090-1091*  
   mechanism of elaboration, *11:1095-1096*  
   missed abortion and, *11:1089-1090*  
   in normal pregnancy, *11:1086-1087*  
   poor obstetrical history and,  
     *11:1091-1092*  
   threatened abortion and, *11:1087-1089*

**Volume 10**, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

**Volume 11**, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

**Volume 12**, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- Diastolic murmurs in pregnancy, 11:972
- Diet in heart disease with pregnancy, 11:914
- Diethylstilbestrol in dysmenorrhea, 12:715
- Digitalis in heart disease with pregnancy, 11:915, 1021-1022
- Dihydroergotamine, 11:44
- Dilation and curettage, 12:900  
postoperative catheterization, 10:193, 199
- Dimenhydrinate (Dramamine), affecting labor, 11:49
- Diuretics in heart disease with pregnancy, 11:915, 1023
- Diverticula, 10:210, 212, 214
- Diverticulitis, 10:545-549, 638
- Diverticulosis in elderly patients, 10:544-546
- Doppler ultrasound, with external tocography, 11:1158-1164
- Dose rate probe detectors, 10:976-982
- Dosimeters, integrating, 10:982-984
- Drainage  
extraperitoneal, in postoperative infections, 12:280-281  
postoperative, 10:195-198
- Dribbling, *see* Urinary incontinence
- Ductus arteriosus defects in pregnancy, 11:926-927
- Dye dilution studies of cardiac output in pregnancy, 11:926-927
- Dysfunctional uterine bleeding, 12:901
- Dysmenorrhea, 11:25; 12:708-722  
etiology of, 12:710-713  
psychogenic factors in, 12:712, 735-737  
secondary or acquired, 12:718-722  
symptoms of, 12:709  
treatment of, 12:713-718
- Dyspareunia and infertility, 12:881
- Dysplasia, cervical, cytologic studies in, 12:305
- Echo patterns of tumors, *see* Ultrasonics
- Eclampsia  
in acute renal failure, 11:563  
blood lactate in, 11:464  
glomerular lesion in, 11:477-480, 506-507  
hemolytic jaundice in, 11:493  
renal morphology in, 11:506-507  
*See also* Preeclampsia; Toxemia of pregnancy
- Ectopic pregnancy, *see* Pregnancy—ectopic
- Edema in pregnancy, 11:574-575  
of lower extremities, 11:975  
pulmonary, 11:1023
- Electrocardiography, fetal, 11:1158
- Electroencephalograms in precocious puberty, 11:801, 811
- Electrolytes, serum, in fetus, 11:1189-1190
- Embolism  
air, in pregnancy, 11:997-998  
amniotic fluid, 11:1000-1001  
fat, in pregnancy, 11:998-999  
from lymphography, 12:384-385  
pulmonary  
diagnostic indications of, 11:251-252  
incidence, 11:257-258, 281-282  
postoperative death and, 11:235-236  
versus pulmonary infarct, 11:251, 267-268
- Emergencies, surgical, in pregnant cardiac patients, 11:1041-1046
- Endocrines  
affecting fetus, 11:1106-1119  
chorionic gonadotropin, 11:1110-1111  
cytologic evaluation, 11:1113-1118  
estriol, 11:1106-1110  
human placental lactogen, 11:1112  
progesterone and pregnanediol, 11:1112-1113  
cytology, hormonal, *see* Cytology
- emotions affecting ovarian hormones, 11:689-695
- estrogen, *see* Estriol; Estrogen
- gonadotropic, *see* Gonadotropins
- hirsutism and, 12:800-822  
hormone therapy in gynecologic cancer, 11:334, 335, 439-452  
infertility and, 12:900-902  
treatment of, 12:919  
in interstitial cystitis, 10:186  
menstrual cycle and, 12:710, 741-750  
nervous control of hormone release, 11:24, 689-695  
neuroendocrine mechanism in puberty, 11:770-772, 796, 855-859  
ovulation detection and, 12:750-752  
premenstrual tension and, 12:729  
progesterone hormones in peripheral plasma, 10:33-34  
*See also specific hormones*
- Endometrial malignancy  
chromosomes in, 12:445  
cytologic studies in, 12:310-311

- Endometriosis  
 of bladder, 10:208  
 infertility and, 12:878  
 pelvic dysmenorrhea in, 12:720  
 of urethra, 10:233
- Endometrium, 10:625-639  
 biopsy of, infertility and, 12:860,  
 887-889, 898  
 cancer of, *see* Cancer—endometrial  
 effect of oral contraceptives on,  
 11:655-658
- Endoscopy  
 aminoscopy, 12:527-532  
 clinical research with, 12:547-548  
 fiber optics and, 12:474, 511, 538-  
 541  
 heating of tissue in, 12:481-483  
 instrumentation for, 12:463-483,  
 538-547  
 laparoscopy, 12:514-526  
 photography with, 12:470-472  
 quality of image in, 12:476-480  
 quartz rod, 12:533  
 record keeping and, 12:545  
 reflector devices for, 12:466-469  
 for reproductive physiology re-  
 search, 12:548-549  
 teaching with, 12:474, 549  
 television with, 12:472-474, 541-544  
*See also* Culdoscopy
- Energy response, 10:975-976
- Energy response, 10:975-976
- Enovid, *see* Mestranol
- Enterocoele in elderly female, 10:488  
 after vaginal hysterectomy, 10:492-  
 493
- Enzymes  
 deficiencies, in adrenal disorders,  
 12:777-779, 782-783  
 functions in pregnancy, 11:1081-1104  
 alkaline phosphatase, 11:1098-  
 1101  
 diamine oxidase, 11:1081-1098  
 oxytocinase, 11:1101-1104  
 in ovarian carcinoma, 12:951-953,  
 963-964  
 ovulation and, 10:357-359, 677
- Epidural block, 12:606-610
- Epinephrine as uterine relaxant, 11:50-  
 51, 53
- Epitestosterone, 12:810
- Ergometrine, 11:44, 47  
 effect on labor, 11:44-45
- Ergot derivatives  
 effect on labor, 11:44-45  
 effect on puerperal uterus, 11:137-  
 140
- Ergotrate, uterine effect, 11:44, 137-140
- Erythrocyte inclusions, *see* Heinz  
 bodies
- Erythromycin in pelvic infections,  
 12:222
- Erythropoietin in amniotic fluid,  
 11:1200
- Escherichia coli* and urinary tract infec-  
 tions, 10:167, 172
- Estradiol, 10:370  
 effect on gonadotropin levels, 11:647  
 glucocorticoid excretion and, 11:489  
 ovulation inhibition and, 11:633, 641  
 sodium retention and, 11:465  
 uptake of, nonsteroidal estrogen an-  
 tagonists affecting, 10:82-84
- Estriol, 10:40, 44-45, 370  
 activity in pregnancy, 11:1106-1110  
 in amniotic fluid, 11:1110, 1200-  
 1201  
 in blood, 11:1109-1110  
 in urine, 11:1106-1109
- Estrogen  
 administration in climacteric,  
 10:588-590  
 administration in nonpregnant  
 women, 10:91  
 affecting vaginal smear in pregnancy,  
 11:1116, 1137  
 in aging female, 10:472-475, 477-478  
 antagonists, nonsteroidal, 10:74-85  
*See also* Clomiphene citrate  
 assays for, 10:371-373, 695-697  
 biologic effect, 10:370-371  
 enzyme effect, 10:677  
 excretion in menstrual cycle, 12:710,  
 743  
 exogenous, and pseudoprecocious pu-  
 bert, 11:805  
 fetal precursors, 10:70, 71, 675  
 glucocorticoid excretion and, 11:489  
 interrelationship with gonadotropins,  
 12:749

Volume 10, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

Volume 11, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

Volume 12, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.



- levels of, 10:298, 299
- maternal precursors, 10:70, 71
- mechanism of action, 10:676-678
- metabolism, 10:675
- natural and ovulation inhibition, 11:641
- after oral contraceptive therapy, 11:648
- ovulation inhibition and, 11:641-642
- in peripheral plasma, 10:30
- placental, 10:675-676
- plasma levels in menstrual cycle, 12:747-749
- progesterone administration, 10:76, 374
- puberty and, 11:857-859
- relationship with RNA, 10:677-678
- role of, 10:74-76
  - in hirsutism, 12:810-811
- sequential therapy for contraception, 11:641-642
- therapy with
  - in atrophic vaginitis, 12:213-215
  - in dysmenorrhea, 12:715
  - in hirsutism, 12:821
  - 17-hydroxycorticosteroid secretion and, 10:91-92
- type of, 10:370
- urinary excretion
  - in menstrual cycle, 10:382-383
  - in pregnancy, 10:60, 68-70, 298
  - uterine effect, 11:58
- Estrone, 10:370
- Ether
  - in obstetrics, 12:598
  - uterine effect, 11:64
- Ethinyl estradiol, *see* Estradiol
- Ethyl alcohol as uterine relaxant, 11:53, 55, 56
- Ethylene effect on late labor, 11:64
- Ethynodiol diacetate and gonadotropin levels, 11:647
- Eversion, 10:749
- Exfoliative cytology, *see* Cytology
- Extracorporeal circulation in pregnant cardiac patients, 11:917-918
- Fallopian tubes
  - in aging, 10:464
  - choriocarcinoma in, 10:281, 283-284, 285
  - infertility and, 12:860, 889-897
  - treatment, 12:916-917
  - inflammation, 10:588-589
  - ligation, *see* Tubal ligation
  - oral contraceptives affecting, 11:660
- Fallopian tube in pregnancy patients, 11:964, 1056
- Familial male hermaphroditism and primary amenorrhea, 11:844, 845
- Fat embolism in pregnancy, 11:998-999
- Female role in infertility, 12:869-877, 909
- Feminization, testicular, 12:696
- Fern Test, 12:885, 899
- Fertility
  - cancer chemotherapy and, 11:416
  - future, after oral contraceptive use, 11:719-720
  - in hemoglobinopathies, 12:67, 115, 128
  - inhibition of
    - by female sex steroids, 11:632, 633
    - by progestogens, 11:637-638
- See also* Infertility
- Fetal death
  - in abruptio placentae, 11:1001-1002
  - current assessment, 11:1069-1071
  - heart disease in mother and, 11:911-912, 1026-1027, 1030, 1031-1035, 1057, 1059
  - hormonal cytology in, 11:1136-1137
  - urinary estriol levels in, 10:44
- Fetus
  - acid-base balance, in labor, 11:168-190
  - adrenal glands in, 10:52-55
  - amniotic fluid studies, *see* Amniotic fluid
  - anencephalic, and low estrogen secretion, 10:68-69
  - biochemical indices of condition, 11:1182-1202
    - amniotic fluid, 11:1193-1202
    - blood, 11:1184-1193
  - death of, *see* Fetal death
  - effects of folic acid deficiency in pregnancy, 11:1143-1152
  - electrocardiography of, 11:1158
  - endocrine indices of environment, 11:1106-1119
    - See also* Endocrines
  - heart rate of
    - deceleration patterns, 11:148-158
    - electronic evaluation of, 11:145-165
    - patterns of, 11:146-148
    - ultrasonic monitoring of, 11:1154-1164
  - human chorionic gonadotropin in, 10:125
  - identification of high-risk fetus, 11:1069-1079, 1096-1097, 1118



- malformations, *see* Malformations—fetal
- maternal bacteriuria and, 11:543
- maternal diabetes and, 11:463-464
- maternal renal disease and, 11:600-602
- normal, definition of, 11:171-181
- 16-OH-DAS in, 10:57-58
- oral contraceptives affecting, 11:705-706
- oxygen transfer, 11:1167-1171
- physiologic acidosis of, 11:177-181
- placental gas transfer studies, 11:1165-1179
- See also* Placenta
- thiazide therapy and, 11:572-574
- ultrasonic monitoring of, 11:1154-1164
- Fibrillation, atrial, in pregnancy, 11:921
- Fibrin embolism in pregnancy, 11:999-1000
- Fibrinase (Factor XIII), 11:211
- and clot stability, 11:218-219
- Fibrinogen (Factors I), 11:207, 209
- radioiodinated, for detection of venous thrombosis, 11:253-254
- Fibrinolysin in pregnancy, 11:996
- Fibrinolytic compounds in thromboembolic disease, 11:275
- Fibrosis, idiopathic retroperitoneal, 10:175, 214, 239, 248
- Fistulas
- bladder, 10:547-548, 590-591
- postoperative, 10:590-591
- salpingo-colic, 10:548
- ureterovaginal, 10:528-530, 548
- vesicovaginal, 10:527, 548, 935-936
- and vaginal carcinoma, 10:662
- Flagyl in trichomoniasis, 12:203
- Flaxedil for cesarean section, 12:601
- Fluid retention, premenstrual, 10:374
- Fluorine, radioactive, in bone scans, 12:411
- 5-Fluorouracil in gynecologic cancer, 11:338, 348, 363-364, 371, 373-375
- Fluorene for cesarean section, 12:599
- Folic acid deficiency in pregnancy affecting fetus, 11:1148
- fetal folate requirements and, 11:1147-1148
- folate determination, 11:1145-1147
- implications of, 11:1150
- incidence of, 11:1143-1145
- maternal complications and, 11:1149
- vitamin supplements in, 11:1151
- Follicle stimulation hormone (FSH), 11:632
- assay, 10:404-405, 692; 12:746-747
- effect on genital tract, 10:366-369
- excretion patterns of, 12:743-744
- human, 10:128-129
- hypothalamic regulation of, 10:669-670
- interrelationships, 12:747-750
- in normal ovulatory cycle, 11:646
- oral contraceptives and, 11:647
- pituitary, 10:670-671
- human, 10:401-414
- preparation and purification, 10:405-406, 670-672
- releasing factor, 10:112-113; 12:788-790
- role in ovulation, 10:361-363
- test for evaluating ovulatory failure, 10:403-404
- in thyroid disease, 12:755-756
- urinary, 10:671-672
- Forbes-Albright syndrome, 12:702, 794
- Frankenhauser's plexuses, 11:16
- Fundal factor in infertility, 12:886-889
- treatment of, 12:91-916
- Fungus infections, 12:204-210, 235-236
- Galactorrhea, 12:794-795
- Gallamine for cesarean section, 12:601
- Gallium, radioactive, in bone scans, 12:411
- Gamma globulin
- fetal levels of immunoglobulins, 11:1192
- immunofluorescent studies, 11:524-526
- Gas
- exchange in pregnancy, 11:975-976
- transfer, placental, 11:1165-1179
- Gastric contents, aspiration of, in anesthesia, 11:1002-1008
- Gastrointestinal tract, 10:555, 556

**Volume 10**, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

**Volume 11**, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

**Volume 12**, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- Geiger counter, 10:981-982
- Genetic counselling, 12:70-72
- Genetic defects, amenorrhea in, 12:695-700
- Genetics, population, 12:211, 229, 230
- Genitalia
- ambiguous external, in CAH, 11:825-828
  - in female precocious puberty, 11:786-788
- Globulin, *see* Gamma globulin
- Glomerular filtration rate in pregnancy, 11:461-466, 490, 492
- assessment of, 11:550-552
  - in preeclampsia, 11:516
  - in presence of glomerular lesions, 11:492-493
- Glomerulonephritis, 11:475
- acute, and pregnancy, 11:583, 603
  - chronic, and pregnancy, 11:583-584, 603
  - immunofluorescent study of, 11:526-527
- Glucose
- in fetal blood, 11:1190
  - infusions affecting acidosis, 11:121
  - secretion in pregnancy, 11:463-464, 552-553
- Conadal defects and amenorrhea, 12:695-700
- Conadal dysgenesis, *see* Turner's syndrome
- Conadotropins
- agglutination-inhibition tests for, 10:121-122, 305-307
  - assay of, 10:690-695
  - in menstrual cycle, 12:744-747
  - clomiphene affecting, 10:78, 390-391
  - human chorionic (HCG), 10:123-126
  - in abnormal pregnancy, 10:310-311
  - bioassay, 10:303-305
  - immunoassay, 10:305-311, 684-685, 693-694
  - for induction of ovulation, 10:392, 401
  - levels affecting fetus, 11:1110-1111
  - in molar pregnancy, 10:272
  - in normal pregnancy, 10:307-310
  - human menopausal, 10:684-686, 688
  - ovarian overstimulation with, 10:686
  - immunoassay of, 10:119-121, 291-294
  - interrelationship with progesterone, 12:750
  - nonsteroidal estrogen antagonists affecting, 10:78-79
  - in normal menstrual cycle, 10:383-384
  - oral contraceptives affecting, 11:647-648
  - in pseudoprecocious puberty, 11:810-811
  - puberty and, 11:857-859, 865
  - releasing factors, 12:788-790
  - secretion of, 10:74-75, 114-116
  - in thyroid disease, 12:755-756
  - trophoblastic neoplasms affecting, 10:290, 291-296
  - urinary, 10:692
- Gonococcal infections, 12:211, 229, 230
- Granuloma inguinale, differential diagnosis of, 12:175-176
- Granulosa-cell tumors and pseudoprecocious puberty, 11:806-807
- Growth in puberty, 11:775, 777, 796, 855
- precocious, 11:788
- Gynecography, 12:896-897
- after culdoscopy, 12:493
- Hageman factor (Factor XII), 11:210
- Hair growth, 12:800-801
- See also* Hirsutism
- Halothane, 12:598, 599
- uterine effect, 11:64-65
- Hamartoma and pseudoprecocious puberty, 11:800
- Heart block in pregnancy, 11:921-922, 1056
- implantation of pacemaker, 11:1041-1046
- Heart disease in pregnancy, 11:910-922
- abortions in, therapeutic, 11:918-919, 979, 1017, 1049-1050, 1061
  - anesthesia in, 11:921-921, 940-966
  - See also* Anesthesia
  - arrhythmias, 11:921-922, 969
  - anesthesia in, 11:965
  - atrial septal defect, 11:1052, 1053
  - coarctation of aorta, 11:1054-1056
  - congenital disease, 11:1048-1062
  - cor pulmonale, 11:992-1008
  - See also* Cor pulmonale
  - diagnosis of, 11:912-913
  - ductus arteriosus defects, 11:964, 1053
  - effects on infant, 11:911-912, 1026-1039, 1057, 1059
  - heart block, 11:921-922, 1041, 1056
  - incidence of, 11:911, 978-980
  - labor and delivery in, 11:919-921
  - medical management of, 11:913-915
  - mitral valvulotomy in, 11:916-917, 978-990, 1018, 1041-1046

- mortality from, 11:911-912  
 obstetric management, 11:918-919  
 pulmonic stenosis, 11:1052-1053  
 rheumatic heart disease, 11:1010-1025  
 surgery in, 11:915-918, 1060-1061  
   emergency, 11:1041-1046  
   results of, 11:1051  
 tetralogy of Fallot, 11:964, 1056  
 ventricular septal defect, 11:1053-1054  
*See also* Cardiovascular signs
- Heart failure  
   in elderly surgical patient, 10:483  
   in pregnancy, 11:963, 1029
- Heart rate  
   fetal, *See* Fetus—heart rate of  
   in pregnancy, 11:969
- Heart sounds in pregnancy, 11:969
- Heinz bodies, 12:25, 28-29, 44  
   demonstration of, 12:80-82
- Hematocrit  
   fetal, 11:1190  
   in pregnancy with heart disease, 11:1028-1029
- Hematuria in interstitial cystitis, 10:188
- Heminephrectomy for ectopic ureter, 10:150, 153
- Hemodynamics, cardiovascular, in pregnancy, 11:924-937, 943-944, 1011-1013  
*See also* Cardiac output
- Hemoglobin  
   electrophoresis of, 12:50-51, 103-110  
   fetal levels of, 11:1191  
   functional properties of, 12:17-19, 42-44, 51-52  
   genetics of, 12:19-20, 21, 50-58  
   Heinz body formation, 12:28-29, 44, 80-82  
   sickle cell test, 12:77-80  
   solubility determinations, 12:110-112  
   unstable, 12:44-46  
   variants, basis for, 12:21-23, 29-46, 54-55
- Hemoglobin A  
   amino acid substitutions, 12:21, 52  
   chains of, 12:15-16  
   and hemoglobin S, 12:19, 20, 34, 123  
   in sickle-thalassemia, 12:34
- Hemoglobin A<sub>2</sub>, 12:56-58  
   in beta-thalassemia, 12:24-25, 60, 115  
   quantitative determinations, 12:99-103  
   in sickle-thalassemia, 12:34
- Hemoglobin Bart's, 12:26-27, 29, 61-62, 115, 119
- Hemoglobin C, 12:21, 37, 52, 80  
   and hemoglobin S, *see* Hemoglobin S
- Hemoglobins Capetown, Chesapeake, Kansas, Kempsey, Ranier, and Yakima, 12:42-43
- Hemoglobin CC disease, 12:134, 150-152
- Hemoglobin D, 12:31, 36  
   an hemoglobin S, 12:31, 36, 53
- Hemoglobin E and alpha thalassemia, 12:62
- Hemoglobin F, 12:53-56  
   in beta thalassemia, 12:24-25, 56, 59, 115  
   determinations of, 12:83-85, 88-98  
   diseases with, 12:56  
   in hemoglobin SS disease, 12:135  
   methemoglobin levels and, 12:91-96  
   persistence of, 12:36-37, 56  
   in pregnancy, 12:56  
   in sickle-thalassemia, 12:34, 56
- Hemoglobin Freiburg, 12:23
- Hemoglobin Gun Hill, 12:23, 46
- Hemoglobin H disease, 12:28-29, 61-115
- Hemoglobin Lepore, structure of, 12:20, 21-22
- Hemoglobin M, 12:40-41
- Hemoglobin Memphis, 12:32
- Hemoglobin S, 12:21, 29-35, 52, 124  
   hemoglobin A and, 12:19, 20, 34, 123  
   hemoglobin C and, 12:19, 20, 31-32, 35-36, 52, 124, 141-149  
   complications of pregnancy, 12:145-148  
   mortality in, 12:141, 142, 144-145  
   in Negro, 12:64-65  
   onset of symptoms, 12:143-144  
   reproductive experience in, 12:142

**Volume 10**, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

**Volume 11**, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

**Volume 12**, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- therapy for anemia, 12:148-149  
 hemoglobin D and, 12:31, 36, 53  
 with hemoglobin F persistence, 12:36-37  
 in sickle-thalassemia, 12:34  
 Hemoglobin SS disease in pregnancy, 12:135-140  
 Hemoglobinopathies  
   diagnostic methods, 12:76-113, 125-126  
   pathophysiology of, 12:15-48  
 Hemolysis in hemoglobinopathies, 12:32, 44, 138  
*Hemophilus vaginalis* vaginitis, 12:210  
 Hemorrhage  
   at delivery, 11:125  
   uterine, cesarean hysterectomy in, 12:620, 643, 649, 656, 680  
 Henderson-Hasselbach equation, 11:111-112  
 Heparin in thromboembolic disease, 11:237-238  
   in pregnancy, 11:293-294, 301-307, 995-996  
   in prophylactic procedures, 11:240-242  
 Herpes virus infections, 12:162-168  
 Hirsutism, 12:800-822  
   androgen role in, 12:802-810  
   corticosteroid role in, 12:811-812  
   estrogen role in, 12:810-811  
   idiopathic, from androgens, 10:30-31  
   17-ketosteroid excretion in, 12:773, 813  
   laboratory investigations in, 12:812-820  
   progesterone role in, 12:812  
   psychologic factors in, 12:803  
   treatment of, 12:820-822  
 Histamine, fetal production of, 11:1096  
 Histology  
   correlation with cytology, 12:304-307  
   of radiated tissues, 12:337-340  
 Hodgkin's disease and incidence of pregnancy, 11:416-417  
 Hormones, *see* Endocrines  
 Hospital admissions, routine cytologic screening of, 12:316  
 Hum, venous, in pregnancy, 11:972-973  
 Human chorionic gonadotropin, *See* Gonadotropins  
 Human follicle stimulating hormone (HFSH), 10:128-129  
   *See also* Follicle stimulating hormone  
 Human menopausal gonadotropin (HMG), 10:684-686, 688  
   ovarian overstimulation with, 10:686  
 Human pituitary follicle stimulating hormone (HPFSH), 10:401  
   for induction of ovulation, 10:402-414  
   ovarian effect, 10:407-408  
 Human placental lactogen (HPL), *see* Lactogen, human placental  
 Hyaline membrane disease of infants, 11:1033  
 Hydatidiform mole, 10:269  
   abdominal hysterotomy in, 10:319  
   choriocarcinoma with, 10:270  
   clinical signs, 10:313  
   curettings from, 10:269-270, 271-272, 274  
   diagnosis and evaluation, 10:269-270, 313-316, 321  
   elevated HCG excretion, 10:314, 315  
   evacuation routed, 10:316, 318-319, 321  
   exuberant trophoblastic activity, 10:269  
   foci of trophoblast within myometrium, 10:274, 276  
   follow-up, 10:320-321, 322  
   human placental lactogen in, 10:320-321, 322  
   hysterectomy for, and evidence of invasion, 10:272  
   incidence, 10:313  
   invasion of vascular channels, 10:272-273  
   laboratory test, 10:313  
   positive, HCHG titer in, 10:272  
   prophylactic chemotherapy, 10:319-320  
   radiography in, 10:314, 316, 317-318  
   recent developments in management, 10:313-322  
   subsequent pregnancy and, 10:283-284  
   subsequent trophoblastic and neoplasia, 10:323  
   thyroid function and, 10:296-298  
   toxemia and, 11:483  
   vaginal nodule with, 10:280-281  
 Hydrogen ion, *see* pH levels  
 Hydronephrosis in cervical carcinoma, 12:430-431  
 Hydrops fetalis with hemoglobin Bart's, 12:26-27, 29, 61, 115, 119  
 Hydroxycorticosteroid levels in pregnancy, 10:89, 91, 92, 94-95  
 17 Hydroxycorticosteroid excretion, 12:781-782  
 Hydroxylase deficiency, 11:822-825  
   in adrenal disorders, 12:777, 782-783

- Hydroxysteroid dehydrogenase deficiency, and CAH, 11:824
- Hyperparathyroidism in elderly, 10:471
- Hypertension  
 in anesthesia, 12:615  
 bacteriuria and, 11:544  
 with congenital adrenal hyperplasia, 11:818  
 in elderly surgical patient, 10:481-483  
 in pregnancy, 11:479-481, 519, 598  
 anesthesia in, 11:964-965  
 renal morphology and, 11:514-516, 519
- Hypnosis in pregnant cardiac patients, 11:958
- Hypnotics for analgesia, 12:595, 600-601
- Hypochloremic acidosis, 10:217, 224
- Hyponatremia, fetal, 11:572
- Hypotension  
 in anesthesia, 12:616  
 supine syndrome of pregnancy, 11:932-933, 934; 12:605-606
- Hypothalamus, 10:106-108, 113-116  
 idiopathic dysfunction, and primary amenorrhea, 11:864-865  
 menstrual disorders and, 12:693, 741, 786-798  
 pituitary activity and, 10:363-365, 669  
 puberty and, 11:771-772, 801, 856-859
- Hypothyroidism  
 amenorrhea and, 12:756-758  
 in old age, 10:470  
 precocious puberty and, 12:758-760  
 pseudoprecocious puberty and, 11:802-803
- Hysterectomy  
 in cervical cancer, 10:922-923  
 cesarean, 12:573-687  
 in abruptio placenta, 12:620, 640, 671-672  
 advantages in, 12:631  
 age distribution of patients, 12:638, 656, 678-679  
 anesthesia for, 12:590-617  
 blood loss in, 12:656, 668, 680  
 in Boston Hospital for Women, 12:652-659  
 in Charity Hospital in New Orleans, 12:635-651  
 comparison of procedures, 12:580  
 complications of, 12:660-674  
 disadvantages in, 12:631  
 elective, 12:641-642  
 emergency, 12:642-643  
 evolution of, 12:575-588, 618-619  
 in hemorrhage, 12:620, 643, 649, 656, 680  
 hospital stay after, 12:646  
 improvements in, 12:582-583  
 incidence of, 12:639, 653-654, 677-678  
 incision for, 12:623-628, 657, 669  
 indications for, 12:583-586, 619-623, 640-643, 648-649, 653-656, 678-680  
 in infections, 12:622, 648, 658, 672  
 in Lutheran Hospital of Milwaukee, 12:677-681  
 in malignancies, 12:622, 649, 658  
 maternal mortality from, 12:464-647, 666  
 modern application of, 12:586-588  
 Müller procedure, 12:577-578  
 operating time for, 12:646, 657, 680  
 operative complications of, 12:643-644, 649-650, 661-662, 668-671, 680-681  
 parity of patients, 12:638, 655  
 peritonization of cervical stump, 12:583  
 Porro operation, 12:576-578, 618-619  
 postoperative complications, 12:645-648, 650, 656-657, 662-663, 673  
 procedures in, 12:623-631, 638-640, 657-658  
 in ruptures, 12:621-622, 642, 649, 655, 672  
 statistical studies of, 12:578, 585  
 for sterilization, 12:587-588, 642, 649, 655, 677  
 Storer operation, 12:576

Volume 10, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

Volume 11, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

Volume 12, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- transfusions in, 12:644, 669, 680
- tubal ligation compared with, 12:652, 676-687
- in tumors, 12:621, 622, 642, 649, 658
- urinary tract injury in, 12:644, 650, 669-671
- complications after, 10:934-936
- after conization, 12:273-274
- in trophoblastic disease, 10:267
- vaginal, 12:583
  - infection after, 12:269, 275
  - for uterine prolapse, 10:491, 492-493
- Idiopathic disorders
  - hypothalamic, and amenorrhea, 11:864-865
  - retroperitoneal fibrosis, 10:175, 214, 239, 248
- Idiopathic factors in infertility, 12:907
- Illumination systems for endoscopes, 12:465-470
- Immunoassay
  - of gonadotropins, 10:119-129
  - See also Gonadotropins
  - in insulin, 10:694
- Immunofluorescent studies of renal biopsy in pregnancy, 11:522-531
- Immunoglobulin levels, fetal, 11:1192
- Immunology, 12:935-936
- Impotency and infertility, 12:853
- Inclusions, erythrocyte, *see* Heinz bodies
- Incompatibility test, 12:886
- Incontinence, urinary, *See* Urinary incontinence
- Indium, radioactive, in lung scans, 12:414
- Infant tissues, oral contraceptives affecting, 11:664, 720, 805
- Infarction, pulmonary, in pregnancy, 11:993
- Infections
  - causing acute renal failure, 11:554, 562
  - from cancer chemotherapy, 11:348
  - in heart disease with pregnancy, 11:914-915, 1023
  - postoperative routes of, 10:195-198
  - prevention of, in catheterization, 10:198
  - renal, in pregnancy, 11:545-546
  - respiratory, in elderly surgical patient, 10:485
  - of urachus, 10:214
  - in uretericulae, 10:156-157
  - urinary tract, *see* Urinary tract
- Infertility, 12:851
  - adrenal glands affecting, 10:88
  - Cushing's syndrome and, 10:97
  - definition of, 12:852
  - factors
    - cervical, 12:881-886, 913-914
    - endocrine, 12:900-902
    - fundal, 12:886-889
    - idiopathic, 12:907
    - ovarian, 12:897-900
    - pelvic, 12:878-879
    - psychogenic, 12:902-907
    - tubal, 12:889-897
    - vaginal, 12:879-881, 913
  - investigation of, 12:852-855
  - management of, 12:857, 908
  - ovarian factor in, 10:345-346
  - patient's visit to doctor, initial husband, 12:864-869, 909
  - investigation, 12:859-864
  - preparatory data, 12:857-859
  - wife, 12:869-877, 909
  - tests for, 12:856, 907
  - treatment of
    - cervical factors, 12:913-914
    - endocrine factors, 12:919
    - fundal factor, 12:915-916
    - hostile mucus, 12:914-915
    - male factor, 12:911-913
    - ovarian factor, 12:917-918
    - psychogenic factor, 12:919-920
    - tubal factor, 12:916-917
    - vaginal factors, 12:913
  - See also Abortion
- Inhalation anesthesia, 12:593-594, 596, 600
- Instruments
  - for culdoscopy, 12:484-487, 504
  - for endoscopy, 12:463-483, 538-547
  - for laparoscopy, 12:514-517
- Insulin, radioimmunoassay of, 10:694
- Intercourse and infertility, 12:853
- Interstitial cell stimulating hormone (ICSH), 10:361
- Intestinal tract, 10:555, 556
- Intrauterine contraceptive device (IUD), 11:627, 685
  - pelvic infection and, 12:179-195
- Intrauterine pressure studies, 11:35, 40, 41
- Invasive mole, 10:269, 271, 272
- Iodinated rose bengal in liver scans, 12:405-406
- Iodine, protein-bound, in menstrual cycle, 10:376
- Iodine test and colposcopy, 10:812

- Iron deficiency  
   in hemoglobinopathies, 12:117, 129  
   in pregnancy, 12:34, 129  
 Irrigation therapy, postoperative,  
   10:197-198  
 Irving tubal ligation, 12:685  
 Isotopes, radioactive, *see* Radioisotope studies  
 Isoxsuprine as uterine relaxant, 11:50,  
   52-53  
 Jaundice in pregnancy, 11:493, 502-503  
 Karotypes, 12:436  
   bizarre, in chromosomes of CIN,  
     10:776-781  
 Karotyping methods, 12:451-456  
 17-Ketosteroids, 10:40-42  
   excretion of, 12:773-774  
     in adrenal disorders, 12:775-777,  
       779  
     in hirsutism, 12:773, 813  
 Kidney  
   absence of, 10:174  
   ammonia excretion, 11:488, 553  
   biopsy of, *see* Biopsy—renal  
   creatinine clearance studies, 12:427-  
     428  
   diabetic nephropathy, and fetal mor-  
     tality, 11:602-603  
   diseases of  
     antenatal measures, 11:591-592  
     counseling pregnant patients,  
       11:594-608  
     pathogenesis of, 11:527-529  
     in pregnancy, 11:529-531, 545-546  
     pregnancy after, 11:579-592  
     prevention of, 11:596  
     sterilization and, 11:596  
     therapeutic abortion and, 11:595-  
       596  
   duplicated, and ectopic ureter,  
     10:148, 153  
   dysfunction, contraindicating antibac-  
     terial therapy, 10:178  
   ectopic, 10:202-203  
   embryology of, 11:587  
   excretion of renin and erythrocyte-  
     stimulating factor, 11:489-490  
   failure, acute, 11:553-566, 606-607  
   function of, normal, 11:487, 550-553  
     circadian rhythm of, 11:468-470  
     impaired by cancer chemotherapy,  
       11:348  
     in pregnancy, 11:461-470  
   function tests, 12:423-428  
   glomerulonephritis, *See* Glomerulo-  
     nephritis  
   glomerulus lesions, 11:492, 511-514  
   in gynecologic cancer, 12:423-432  
   hereditary nephropathy in preg-  
     nancy, 11:475  
   hypertension and, 11:514-516  
   intravascular sickling in, 12:34, 127  
   intravenous pyelogram, 12:423  
   lesions in pregnancy, 11:475-477,  
     478, 480, 492, 497  
     immunofluorescent studies of,  
       11:527-531  
   malformation of, and pregnancy,  
     11:587-590  
   metastatic hypernephroma, 10:203-  
     204  
   neoplasia in aged female, 10:524-  
     525  
   nephrectomy, pregnancy after,  
     11:586-587  
   nephrosclerosis and pregnancy,  
     11:605-606  
   nephrotic syndrome in pregnancy,  
     11:482, 483, 603, 604-605  
   normal glomerulus, 11:509-510, 512  
   in ovarian carcinoma, 12:432  
   pelvic, 11:589-590, 607-608  
   polycystic degeneration of, and preg-  
     nancy, 11:584-585, 606  
   pyelonephritis, *see* Pyelonephritis  
   radioisotope renogram, 12:424-427  
   renal plasma flow in normal preg-  
     nancy, 11:461-462, 490  
   solitary, 11:587-589, 607  
   in toxemia of pregnancy, 11:492-493,  
     511, 513-514  
     arteriole alterations and hyperten-  
       sion, 11:476, 477-480  
     glomerular tuft alterations, 11:476  
       477  
   trauma to, and urinary tract infec-  
     tion, 10:170

**Volume 10**, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

**Volume 11**, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

**Volume 12**, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.



- tuberculosis of, and pregnancy,  
11:585, 607
- tubular reabsorption and secretion,  
11:463, 552-553
- in uterine malignancies, 12:428-432
- Klebsiella-Aerobacter* organisms, urinary tract infections with,  
10:167, 172, 178
- Kraurosis vulvae, 10:456-457
- Labor**
- acetylcholine affecting, 11:46-49
- and acidosis, metabolic, 11:116-118
- anesthetics in, *see* Anesthesia
- anticoagulant drugs in, 11:996
- cardiac output in, 11:934-936
- circulatory changes in, 11:1013
- dimenhydrinate affecting, 11:49
- electrical induction of, 11:27-30
- ergot derivatives affecting, 11:41-45
- fetal acid-base balance in, 11:168-190
- in heart disease, 11:919-920, 1023-1024
- maternal acid-base balance in,  
11:110-123
- premature, and drug therapy, 11:22, 50, 52-53
- psychologic effects of, 11:946
- respiration in, 11:118-119
- spontaneous, and uterine activity,  
11:126-128
- uterine blood flow in, 11:96-108
- uteroplacental circulation in, 11:78-94
- uterus in, 11:26-27, 126-130
- See also* Delivery
- Laboratory facilities for cytologic screening, 12:318-324
- Lactate, in fetal blood, 11:1189
- Lactation**
- amenorrhea and, 12:702-704
- oral contraceptives affecting, 11:662-663
- persistent, 12:794-795
- Lactogen, human placental (HPL),  
10:132-141
- in abnormal pregnancy, 10:136
- assay, 10:134-135, 139-140
- in choriocarcinoma of testis, 10:138
- comparison with HCG, 10:136-137
- evidence for placental origin,  
10:133-134
- extraction and purification of, 10:134
- historic development of, 10:132-135
- in hydatidiform mole, 10:136
- as indication of trophoblastic cells,  
10:300
- levels affecting fetus, 11:1112
- mammatropic effects, 10:137-138
- in normal pregnancy, 10:135-136, 138-139, 299-300; 11:462
- physiologic role in pregnancy,  
11:137-139
- similarity to HGH, 10:132, 138
- somatotropic effects, 10:138-139
- Laparoscopy, 12:514-526
- compared with culdoscopy, 12:495, 525
- complications of, 12:519
- in ectopic pregnancy, 12:523-524
- indications for, 12:519
- instrumentation for, 12:514-517
- photography with, 12:514-517
- results of, 12:519-525
- surgical procedures in, 12:524-525
- technique of, 12:517-518
- Laparotomy, exploratory, for cervical cancer, 10:951-853
- Leiomyoma, 10:555
- Leiomyomata uteri and infertility,  
12:878
- Leukoplakia**
- in aging female, 10:458-459
- cervical, cytologic studies in, 12:304
- as precursor of vulvar malignancy,  
10:508
- Libido, and oral contraceptives,**  
11:692-693
- Lidocaine in obstetrics, 12:603**
- Ligation of tubes, *see* Tubal ligation
- Lipid(s) in fetal blood, 11:1191-1192
- Liver**
- acute fatty metamorphosis of, 11:503
- biopsy of, in preeclampsia, 11:496-501
- blood flow in, 11:487, 491-492, 493
- cirrhosis in pregnancy, 11:475
- erythrocyte-stimulating factor and,  
11:490
- estrogen and glucocorticoid excretion in, 11:489-490
- failure, 11:489, 490, 502
- fetal, progesterone metabolism in,  
10:55
- function of, 11:487
- in pregnancy, 11:491-492
- kidney interrelation in pregnancy,  
11:487-504
- metastases to, in choriocarcinoma,  
10:283
- mitochondria of, 11:494-495, 496-497
- necrosis from anesthetics, 12:597, 598, 599
- oral contraceptives and, 11:677-678



- radioisotopic scanning of, 12:404-409  
 in toxemia of pregnancy, 11:493-496  
 urea excretion, 11:487-488  
 uric acid excretion, 11:489  
 urobilinogen excretion, 11:489  
 Lub's syndrome, 11:844, 845
- Lungs**  
 changes in pregnancy, 11:941, 975-976  
 cor pulmonale in pregnancy, 11:992-1008  
 edema in pregnancy, 11:1023  
 embolic from lymphography, 12:385  
 metastases to, ultrasonic studies of, 12:367-369  
 radioisotope scans of, 12:412-415  
 vascular pressures in pregnancy, 11:928, 933-934  
 volumes in pregnancy, 11:941-942  
*See also* Embolism—pulmonary
- Luteal inadequacy**, 12:898
- Luteinizing hormone (LH)**  
 assay of, 12:744-746  
 bioassay of, 10:691  
 excretion patterns, 12:743-744  
 hypothalamic regulation of, 10:699  
 immunoassay of, 10:694  
 immunologic studies, 10:126-128  
 interrelationships  
   with estrogens, 12:749  
   with follicle-stimulating hormone, 12:747  
   with progesterone, 12:750  
 pituitary, preparation of, 10:670-671  
 -releasing factor, 10:109-112, 126-128, 365, 669-670; 12:788-790  
 role in ovulation, 10:361, 362, 369  
 in thyroid disease, 12:755-756  
 urinary, preparation of, 10:671-672, 692
- Luteotropic hormone (LTH)**, 10:361; 11:632  
 inhibiting factor, 10:113-114  
 in normal ovulatory cycle, 11:646  
 oral contraceptives affecting, 11:647
- Lymph node dissection**, pelvic, 10:965-972  
 in cervical cancer, 10:926-928, 947
- Lymphadenectomy** evaluation by lymphography, 12:379-380
- Lymphatic invasion** and tumor virulence, 12:349-350
- Lymphogranuloma venereum**, 12:175-176
- Lymphography**, 12:372-387  
 complications of, 12:384-386  
 current status of, 12:386-387  
 embolism from, 12:384-385  
 identification of vessels, 12:373  
 injection of dye, 12:374  
 after lymphadenectomy, 12:379-380  
 in metastatic carcinoma, 12:375-379  
 in radiation reaction studies, 12:380-381  
 radiography of pelvis after, 12:382-384  
 in recurrent carcinoma, 12:380-381  
 results of, 12:375-384  
 technique of, 12:372-375  
 visualization of lymphatics at surgery, 12:381-382
- Madlener tubal ligation**, 12:684
- Magnesium sulfate**, uterine effect, 11:60-64
- Male role** in infertility, 12:864-869, 909  
 treatment of, 12:911-913
- Malformations**, fetal, and heart disease in mothers, 11:1045, 1058
- Malignancies**, *see* Cancer; Tumors
- Mammary souffle**, in pregnancy, 11:973-974
- Maternal mortality**  
 Addison's disease and, 10:99  
 in heart disease, 11:911-912
- Meconium** detection, amniocentesis for, 12:529-531
- Medroxyprogesterone** affecting gonadotropin levels, 11:647
- Megavoltage radiotherapy** in carcinoma of cervix, 10:958-962
- Megestrol acetate**  
 affecting gonadotropin levels, 11:647  
 antifertility effect, 11:637-638
- Melphalan** therapy, in gynecologic cancer, 11:346  
 in ovarian cancer, 11:354-366
- Menarche**, 11:776

**Volume 10**, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

**Volume 11**, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

**Volume 12**, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- average age of onset, 11:777, 854, 855  
in blind females, 11:770, 854  
explained to adolescent, 11:763-765  
and other pubertal changes, 11:781, 798  
*See also* Menstruation; Puberty
- Mendelian patterns of inheritance, disorders of, and primary amenorrhea, 11:837-845
- Menopause, 12:705-706  
use of oral contraceptives in, 11:729-731
- Menstrual cycle  
endoscopic studies of, 12:547  
hormonal patterns and interactions in, 12:710, 741-750  
onset of menarche in, 12:694  
ovulation detection and, 12:750-752  
reactions to, 12:727
- Menstrual disorders, 12:691-822  
with adrenal dysfunction, 12:771-783  
amenorrhea, 12:693-707  
dysmenorrhea, 12:708-722, 735-737  
hirsutism and, 12:800-822  
hypothalamus in, 12:693, 741, 786-798  
infertility and, 12:853  
premenstrual syndrome, 12:728-735  
psychosomatic aspects of, 12:712, 724-739  
in thyroid disorders, 12:755-768
- Menstruation  
anovulatory cycle, 11:860-861  
cervical mucus changes in, 10:384  
cyclic emotional variations, 11:689-690  
establishment of, 10:361  
hormone levels in, 10:382-384  
protein-bound iodine in, 10:376  
sequence of events in, 10:361-363  
severe bleeding in, 11:226  
urinary pregnanetriol levels in, 10:376-377  
vascular pattern in, 11:78-79
- Meperidine  
in pregnancy with heart disease, 11:948-955  
uterine effect, 11:59-60, 62
- Mepivacaine in obstetrics, 12:603
- Meprobamate interference with colorimetric assay, 10:42
- MER-25, 10:79-82  
mechanism of action, 10:391
- 6-Mercaptopurine therapy in gynecologic cancer, 11:338  
in pregnancy, 11:421
- Mesenteric tumors, 10:556-557
- Mestranol (Enovid), 11:685  
affecting gonadotropin levels, 11:647  
ovulation inhibition and, 11:633, 641
- Metabolic acidosis in labor, 11:116-118
- Metabolites, urinary, assay of, 10:40
- Metaplasia, squamous, cervical, cytologic studies in, 12:304
- Metastatic cancer of the ovary, case history review, 12:972-973, 976-978
- Metastatic disease  
lymphography in, 12:375-379  
radioisotopic scanning of liver in, 12:407-408  
ultrasonic studies in, 12:365-339
- Methemoglobins, 12:40-42, 91-96
- Methergine, 11:44-45
- Methotrexate  
in gynecologic cancer, 11:346  
in pregnancy, 11:420-421  
in metastatic trophoblastic disease, 10:267, 296, 330-338  
in nonmetastatic trophoblastic disease, 10:323-328  
preceding evacuation of molar pregnancy, 10:319-320  
in squamous cell carcinoma, 11:370-371  
tumor response to, 10:276
- Methoxyflurane anesthesia, 12:594, 598
- Metopirone test, 12:1020-1021
- Metronidazole in trichomoniasis, 12:203, 204
- Milk, ejection reflex, 11:15
- Miller-Kurzrock Test, 12:885-886
- Mitral stenosis in pregnancy, 11:1015-1016
- Mitral valvulotomy in pregnancy, 11:916-917, 978-990, 1018, 1041-1046  
criteria for surgery, 11:987-988  
early operative results, 11:982-983  
follow-up of children, 11:983-984, 989, 1045  
follow-up of mothers, 11:984-985, 988  
indications for, 11:981  
long-term maternal outcome, 11:989-990  
obstetric results, 11:983  
operative findings, 11:981-982  
subsequent pregnancies and, 11:985-986, 1051, 1060
- Morphine  
in pregnancy with heart disease, 11:948, 955  
uterine effect, 11:59

- Mortality**  
 in cesarean hysterectomy, 12:646--647, 666  
 in hemoglobinopathies, 12:38, 67, 136, 139, 141-145, 151, 153-155  
*See also* Fetal death; Maternal mortality
- Mucins in ovarian carcinoma**, 12:951-953
- Mucocoele of appendix**, 10:553-554
- Mucus, hostile, and infertility**, 12:915-915
- Müller cesarean hysterectomy**, 12:577-578
- Mullerian duct anomalies and primary amenorrhea**, 11:850-852; 12:698-699
- Murmurs, cardiac, in pregnancy**, 11:970-974
- Muscle relaxants for cesarean section**, 12:601-602
- Mycotic diseases**, 12:204-210, 235-236
- Myocardial reserve response in pregnancy**, 11:929
- Myoglobin, structure of**, 12:15-20
- Myomas, uterine**  
 cesarean hysterectomy in, 12:621, 642  
 dysmenorrhea in, 12:721
- Myometrium**  
 contractility of, 11:86-88  
 characteristics of, 11:97-98  
 drainage from intervillous space and, 11:92-93  
 duration of, 11:103-104  
 frequency of, 11:101-103  
 intensity of, 11:99-101  
 in last month of pregnancy, 11:96  
 oral contraceptives affecting, 11:654-655  
 oxytocin affecting, 10:385; 11:15, 24, 28, 100  
 relationship with UBF, 11:104  
 foci of trophoblast in, 10:274-276  
 nonsteroidal estrogen antagonist effect, 10:82
- Narcotics**  
 for analgesia, 12:595, 613
- in pregnancy with heart disease, 11:948, 954-955
- National Fertility Study**, 11:734-749
- Natriuretic mechanism in pregnancy**, 11:466-468
- Neonate, see** Newborn
- Neoplasms, see** Cancer; Tumors
- Nephrectomy, pregnancy following**, 11:586-587
- Nephritis, see** Glomerulonephritis; Kidney
- Nephroma, metastatic ovarian**, 10:203-204
- Nerves, see** Central nervous system
- Neurectomy, presacral, in dysmenorrhea**, 12:717
- Neuroendocrine mechanism in puberty**, 11:770-772, 786, 855-859
- Neurogenic factors in dysmenorrhea**, 12:712
- Neurologic damage in infants of cardiac patients**, 11:1036
- Newborn**  
 anesthetic agents affecting, 12:600, 601, 603-604, 612-613  
 of cardiac patients, 11:1026-1039, 1057-1059  
 elimination of volatile anesthetics in, 12:599-600  
 after mitral valvotomy in mothers, 11:983-984, 989, 1045  
 syndromes in high-risk infants, 11:1074-1075
- Nitrogen mustard in gynecologic cancer**, 11:346, 356, 370, 422
- Nitrous oxide, placental transfer of**, 11:1172-1175
- Nitrous oxide anesthesia**, 12:594, 596-597
- Node dissection**, 12:932
- Norepinephrine**  
 effect on labor, 11:45-46, 48  
 in uterus, 11:17
- Norethindrone**, 11:634  
 antifertility effect, 11:637-638, 640  
 inhibition of endometrial development, 11:636, 640
- Nucleolar ribonucleic acid (RNA), in ovarian carcinoma**, 12:950-951

**Volume 10**, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

**Volume 11**, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

**Volume 12**, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- Nutritional disorders, amenorrhea in, 12:700
- Obesity  
  endometrial cancer and, 10:628-629  
  in pregnancy with heart disease, 11:1021
- Oil embolism from lymphography, 12:384-385
- Oligospermia and infertility, 12:853
- Oral contraceptives  
  adverse effect, statistical study of, 11:698-711  
  amenorrhea and, 11:648-649, 722  
  anovulation after use, 11:648  
  blood coagulation and thrombophlebitis from, 11:675-677, 701-710, 725-727  
  breast and reproductive system effects, 11:645-664, 722  
  breakthrough bleeding and, 11:720-722  
  candidiasis incidence and, 12:207-208  
  carcinogenic effect, 11:679-680, 704-705  
  cardiovascular effects, 11:674-675  
  Catholic Church and, 11:752  
  chromosomal alterations and, 11:680  
  CNS effects, 11:672, 724  
  common side-effects, 11:698-701, 722  
  diabetogenic effect, 11:673-674  
  discontinuation of, 11:747-749  
  emotional factors and, 11:684-695  
  in England, 11:716-732  
  fallopian tubes and, 11:660  
  fetal effects, 11:705-706  
  gonadotropin levels and, 11:647-648  
  headaches and migraine from, 11:724-725  
  hematologic changes and, 11:672-673  
  in hemoglobinopathies, 12:72, 119  
  hepatic effects, 11:677-678  
  instruction of patient, 11:717-718  
  integral effects, 11:678-679  
  libido and, 11:692-693, 727-728  
  lipid metabolic effects, 11:674  
  medical and metabolic effects, 11:669-752  
  in menopausal women, 11:729-731  
  "morning after pill," 11:629-630  
  nursing infant, effect on, 11:664, 720  
  ovarian function and, 11:649-654  
  personality testing and, 11:693  
  pharmacology of, 11:622-643  
  postpartum use of, 11:720  
  in premenopausal women, 11:729  
  progestogen compounds, 11:628, 671  
  progestogen-estrogen compounds, 11:627-628, 631, 671  
  safety of, 11:627, 692  
  trichomoniasis incidence and, 12:208  
  in United States, 11:734-752  
  urologic effects, 11:680  
  uterine effect, 11:654-660  
  vaginal discharge and, 11:728-729  
  weight changes and, 11:723-724
- Osmolality of fetal blood, 11:1189-1190
- Osteoporosis in aged, 10:476-477
- Ovary  
  abscess of, postoperative, 12:267, 275-276, 279  
  in aging, 10:461-464, 471-478  
  biopsy of, 12:505-507  
  carcinoma of  
    chemotherapy, 12:1003-1016  
    in children, 12:931-932  
    diagnosis, 12:958-971  
    histochemistry, 12:947-953  
    histologic grading, 12:941-947  
    immunology, 12:935-936  
    metastatic, 12:972-978  
    node dissection, 12:932  
    palliative therapy, 12:1038-1048  
    postoperative irradiation, 12:993-1001  
  primary, 12:972-978  
  prophylaxis, 12:965-967  
  radioactive substances, 12:932-933  
  "spill," 12:932  
  staging, 12:935, 937-941  
  steroidogenesis, 12:934-935, 1018-1024  
  surgical treatment, 12:980-991  
  survival factors, 12:935, 1003-1006, 1025-1036  
  terminal, 12:933-934  
  clomiphene affecting, 10:79, 80-81, 393, 395, 399, 686-688  
  dysfunction of, and primary amenorrhea, 11:871-874  
  embryology of, 12:929  
  as estrogen source, 10:369-373, 672-675  
  postmenopausal, 10:472-475, 476  
  fetal progesterone metabolism, 10:55  
  follicular development in, 10:345, 347-349, 350-352, 357, 407, 408  
  function tests in hirsutism, 12:816-817  
  functions of, 10:345  
  in puberty, 11:774  
  infertility and, 12:860, 897-900

- treatment, 12:917-918  
tumors, 12:878-879
- interaction with hypothalamus and pituitary, 11:646-649
- malignancies of  
angiography, 12:393-394  
chromosomes in, 12:445-447  
cytologic studies in, 12:311  
ureteral obstruction in, 12:432
- MER-25 affecting, 10:79-80
- metastatic nephroma of, 10:203-204
- nonsteroidal estrogen antagonists effect on, 10:79-81
- oocytes in, 10:462-464
- oral contraceptives affecting, 11:649-654
- ovarian vein blood, steroid analysis in, 10:34-38
- overstimulation of, by HCG and HMG, 10:686
- phylogenic development of, 12:929-930
- pituitary effect, 10:369
- polycystic disease, 10:31, 393, 395, 399, 679-681  
*See also* Stein-Leventhal syndrome
- progesterone secretion and, 10:373-376, 473, 681-683
- prophylaxis, 12:930-931
- secretory activity, 10:34
- steroidogenesis, 10:672-675, 679-680
- stigma formation and ovulation, 10:349, 352, 354-355  
histologic examination, 10:357, 358
- Ovulation  
anatomy of, 10:347-359  
clomiphene citrate induction, 10:686-688  
corpus luteum formation and, 10:408  
defects, clomiphene therapy for, 10:390-399  
detection of, 10:345  
and hormonal patterns, 12:750-752  
direct evidence of, 10:380-381  
endocrinology in, 10:361-377  
endoscopic studies of, 12:547-549  
enzymes and, 10:357-359  
failure of, 10:345-346  
HPFSII-induction of, 10:401-414  
hypothalamus activity and, 12:787-788  
indirect evidence of, 10:381-387  
induction with HCG, 10:392, 683-684  
inhibitors, 10:361, 681-683  
intrafollicular pressure, 10:355-357  
mechanism of, 10:357, 358  
visualization of, at laparotomy, 10:381
- Oxidase, diamine, in maternal plasma, 11:1081-1098
- Oxygen  
diffusing capacity, placental, 11:1176-1178  
tension of blood, in fetus, 11:1188-1189  
therapy, in heart disease with pregnancy, 11:915  
transfer to fetus, 11:1167-1171
- Oxytocin  
effect on maternal acidosis, 11:122  
effect on nonpregnant uterus, 11:15  
fetal effect, 11:41  
intramuscular route, 11:40-41  
intranasal route, 11:40  
intravenous infusion, continuous, 11:35-39  
intravenous injection, single, 11:35-39  
milk ejection reflex and, 11:15  
myometrial sensitivity and, 11:15, 24, 28, 100  
precautions for use, 11:41-43  
preparations for, 11:43-44  
in puerperium, 11:140-144  
transbuccal route, 11:40  
uterine effect, 10:385; 11:128-130
- Oxytocinase, in maternal plasma, 11:1101-1104
- Pacemaker, cardiac, implanted during pregnancy, 11:1041-1046
- Pain  
in dysmenorrhea, 12:709  
relief of, *see* Anesthesia
- Palliative therapy of advanced ovarian carcinoma, 12:1038-1039  
generalizations, 12:1045-1048  
problems of

Volume 10, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

Volume 11, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

Volume 12, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- fluid accumulations, 12:1043-1044  
gastrointestinal tract symptoms, 12:1042-1043  
newer enlarging mass, 12:1041-1042  
pain, 12:1044-1045  
urinary tract symptoms, 12-1045  
study patients, 12:1039-1041  
PAM therapy for ovarian cancer, 11:356-363  
Pancreas in old age, 10:471  
Pancreatitis, hemorrhagic, from thiazide therapy, 11:573-574  
Panculdoscope, 12:485, 504, 536  
Papanicolaou smear, 10:844; 12:961  
in cervical neoplastic disease, 10:854  
Paraplegia from spinal anesthesia, 12:606, 611  
Parturition, *see* Labor  
Pelvic factors and infertility, 12:853, 878-879, 901  
Pelvic inflammatory disease  
antibiotics in, 12:219-237, 279-280  
anticoagulants in, 12:240-245  
dysmenorrhea in, 12:718-719  
in hemoglobin SS disease, 12:139  
with intrauterine devices, 12:179-195  
postoperative infections, 12:265-281  
steroid hormone therapy, 12:247-251  
thrombophlebitis, septic, 12:231, 240-245  
tubo-ovarian abscess, 12:252-264, 266-267  
viral infections, 12:161-171  
vulvovaginitis, 12:198-217  
Pelvis  
anatomy of, 10:489-490  
cancer of  
posterior dissection of, 10:930-933  
problems encountered, 10:566  
relaxation of  
cervical cancer and, 10:585-588  
in elderly female, 10:488-497  
endometrial cancer and, 10:631-632  
Penicillin in pelvic infections, 12:220, 280  
Penthrane anesthesia, 12:594, 598  
Peritonization of cervical stump in cesarean hysterectomy, 12:583  
pH levels  
fetal, 11:1187-1188  
maternal, affecting fetus, 11:1171-1172  
vaginal changes during ovulation, 10:385  
Phenergan, action of, 12:596  
Phenindione therapy in thromboembolic disease, 11:240  
Phenolsulfonphthalein test, 12:896  
Phenothiazines for analgesia, 12:595  
Phenylbutazone  
in pregnancy, 11:996  
for venous thrombosis, 11:270  
Pheochromocytoma in old age, 10:469  
Phlebitis, 11:204  
in pregnancy, 11:236, 302  
Phonocardiography, fetal, 11:1158  
Phosphatase, alkaline, in maternal plasma, 11:1098-1101  
Photography  
with culdoscopy, 12:493-495, 512  
with endoscopy, 12:470-472  
with laparoscopy, 12:514-517  
Pineal body  
pseudoprecocious puberty and, 11:799-800  
puberty and, 11:772, 784  
Pineal gland, 12:787  
Pituitary gland  
anterior, 10:106-108  
ablation and transplantation, 10:363-364  
in female over 65, 10:467-468  
gonadotropins, 10:368-369  
hypothalamus activity and, 12:787-788  
primary amenorrhea and, 11:862-863; 12:695, 701  
puberty and, 11:772-773, 784, 856-859  
Sheehan's syndrome, 12:795-796  
Pituitary gonadotropin suppression test, 12:1022-1024  
Pituitrin, 11:35  
*See also* Oxytocin  
Placenta, 11:86  
abruptio placentae, 11:1001-1002  
in folic acid deficiency, 11:1149  
maternal renal disease and, 11:601  
affecting cardiac output, 11:930-931  
blood volume in labor, 11:934  
circulation, *see* Uteroplacental circulation  
enzyme levels in, 11:1081-1104  
*See also* Enzymes  
estrogens in, precursors of, 10:60-71  
gas transfer in, 11:1165-1179  
acid-base balance and, 11:1171-1172  
in nitrous oxide anesthesia, 11:1172-1175  
oxygen diffusing capacity, 11:1176-1178

- oxygen transfer to fetus, 11:1167-1171  
 stress affecting, 11:1178  
 sufficiency and insufficiency of, 11:1165-1167  
 transplacental gas gradients, 11:1175-1176  
 HCG produced by, 10:132, 140  
 perfusion technique, 10:62  
 progesterone levels, 10:55-56; 11:466  
 protein hormone production, *see* Lactogen, human placental  
 weight of, and serum HPL, 10:140  
 Placental lactogen, *see* Lactogen, human placental  
 Plasma  
 renin activity in pregnancy, 10:94  
 thromboplastin antecedent, 11:210  
 thromboplastin component, 11:210, 217  
 Platelets, 11:207, 219-220  
 antiheparin activity, 11:211  
 hemostatic process, 11:222-223  
 phospholipid factor, 11:211  
 thrombus, 11:244-245, 262  
 Pneumoperitoneum, diagnostic, 12:491  
 Polycystic ovaries, *see* Stein-Leventhal syndrome  
 Polymyxins, postoperative use of, 12:280  
 Polyostotic fibrous dysplasia and pseudoprecocious puberty, 11:803-805  
 Polyp(s)  
 intestinal, 10:555  
 urethral, 10:229, 231  
 Polyploidy, 12:436  
 Pomeroy tubal ligation, 12:683  
 Porro cesarean hysterectomy, 12:576-578, 618-619  
 Postcoital cervical mucus examination and infertility, 12:853, 859, 882-885  
 Postmature fetus and hormonal cytology studies, 11:1134  
 Postoperative pelvic infections, 12:265-281  
 adnexal infections, 12:269, 275, 278  
 from bacterial contamination, 12:271-272  
 cellulitis, 12:266, 277  
 ovarian abscess, 12:267, 275-276, 279  
 preoperative factors, 12:268-270  
 surgical factors, 12:270-276  
 treatment of, 12:278-281  
 unrecognized salpingitis and, 12:274-275  
 with vaginal surgical approach, 12:269, 275, 277  
 Post thrombotic syndrome, 11:309  
 Posture and dysmenorrhea, 12:711-712  
 Pouch of Douglas, tumors of, 10:559  
 Precipitin tests for human gonadotropins, 10:121  
 Precordial impulses in pregnancy, 11:968  
 Preeclampsia  
 glomerular changes in, 11:483, 508-509  
 hemolytic jaundice in, 11:493  
 hyperuricemia in, 11:519  
 liver biopsy in, 11:494-501  
 prematurity and, 11:542-543  
 renal failure in, 11:554-559, 563-564  
 renal function in, 11:516-519  
 thiazide diuretics in, 11:574-575  
 uric acid secretions in, 11:464, 519, 576  
*See also* Eclampsia, Toxemia of pregnancy  
 Precocious puberty, 12:758-760, 780-793  
 abnormal EEG and, 11:801  
 age of onset, 11:785-786  
 axillary hair in, 11:786  
 body proportions in, 11:788-789  
 definition of, 11:780  
 drug therapy, 11:791-793  
 etiology, 11:782-785  
 external genitalia in, 11:786  
 incidence of, 11:780-782  
 internal genitalia in, 11:786-788  
 linear growth in, 11:788  
 management of, 11:789-793  
 pseudoprecocious, 11:795-812, 815-832  
 psychologic management of 11:790

**Volume 10**, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

**Volume 11**, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

**Volume 12**, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.



- Pregnancy  
 abruptio placentae, 11:601, 1001-1002, 1149  
 acid-base balance in, *see* Acid-base balance  
 Addison's disease and, 10:98-100  
 adenocarcinoma and, 10:636  
 adrenal cortical function in, 10:89-97  
 adrenal hyperplasia and, congenital, 10:100; 11:831  
 air embolism in, 11:997-998  
 aldosteronism in, 10:88, 92-94, 95-97; 11:465-466, 468, 568-570  
 aldosteronism in, primary, 10:100-101  
 amenorrhea in, 12:693-694  
 amniotic fluid studies, *see* Amniotic fluid  
 anticoagulants in, 11:243-244, 292-298, 301, 918, 995-996  
 bacteriuria in  
   asymptomatic, 10:169, 174-175  
   urinary infection and, 11:533-547  
 cancer chemotherapy in, 11:416-425  
 carcinoma in situ and, 10:856-858, 870-876  
 cardiovascular hemodynamics in, 11:924-937, 943-944, 1011-1013  
   *See also* Cardiac output  
 cardiovascular signs in, 11:968-977  
   *See also* Cardiovascular signs  
 catheterization in, hazards of, 11:533  
 cervical changes in, 10:871-872  
 cervical conization and, 10:856-858, 873-875  
 cesarean hysterectomy in, *see* Hysterectomy  
 circulation in, 11:924-937, 943-945, 1011-1013  
 clomiphene-induced, 10:397-398  
 colposcopy in, 10:873  
 cor pulmonale in, 11:992-1008  
   *See also* Cor pulmonale  
 cortisol in, 11:462, 465  
 Cushing's syndrome and, 10:97-98  
 cytologic screening of prenatal patients, 12:313-316  
 cytology in, vaginal, *see* Cytology  
 diabetes and, 10:13; 11:463-464  
 differential diagnosis, 10:285, 287, 288  
 diffuse intravascular clotting in, 11:226-228  
 ectopic  
   HCG levels in, 10:126  
   laparoscopy in, 12:523-524  
 edema in, 11:574-575  
   of lower extremities, 11:975  
   pulmonary, 11:1023  
 endocrine activity in, 11:1106-1119  
   *See also* Endocrines  
 enzyme functions in, 11:1081-1104  
   *See also* Enzymes  
 establishment of, 10:380-381  
 estradio, secretion in, 11:465  
 estrogen secretion in, 10:298; 11:465  
 fat embolism in, 11:998-999  
 fetal risk in, *see* Fetus  
 folic acid deficiency in, 11:1143-1152  
 glucose secretion in, 11:463-464  
 heart in, diseases of, *see* Heart disease in pregnancy  
 hemotologic changes in, 12:116-117  
 hemoglobin F in, 12:56  
 hemoglobin SS disease and, 12:135-140  
 hemolytic jaundice in, 11:493  
 after HPFSH therapy, 10:411-413  
 hypertension and, *see* Hypertension—in pregnancy  
 hypotensive syndrome of, supine, 12:605-606  
 incidence during malignant disease, 11:416-417  
 iron deficiency anemia in, 12:34, 129  
 jaundice in, 11:493, 502-503  
 kidney in, *see* Kidney  
 liver function in, 11:491  
 mammary gland in, 10:137-138  
 mechanisms leading to poor prognosis, 11:542-543  
 metronidazole use in, 12:204  
 mitral valvulotomy in, *see* Mitral valvulotomy  
 molar, *see* Hydatidiform mole  
 multiple  
   clomiphene therapy and, 10:398  
   after HPFSH therapy, 10:411-412  
 natriuretic mechanism in, 11:466-468, 568  
 nephrotic syndrome in, 11:482, 483  
 ovarian tumors with, 10:616-617  
 phlebitis in, 11:302  
 phlebothrombosis in, 11:302-307  
 physiologic changes in, 11:941-946  
 placenta in, *see* Placenta  
 placental lactogen in, 10:135-136, 138-139, 299-300; 11:462  
 plasma 17-hydroxycorticosteroid levels in, 10:89-90  
 post thrombotic syndrome and, 11:309  
 prevention of, feelings about, 11:687



- See also* Contraception  
 progesterone secretion in, 10:47, 48, 97; 11:466, 568  
 proteinuria in, 11:597-598  
 pruritus in, idiopathic, 11:503  
 pseudocystitis, 12:796  
 pulmonary embolism in, 11:307-309, 993  
 punch biopsy in, 10:872  
 pyelonephritis in hemoglobinopathies, 12:34, 130, 138  
 renal function in, 11:461-470  
*See also* Kidney  
 respiration in, 11:941-943  
 rheumatic heart disease in, 11:1010-1025  
 sickle cell disease and, 12:38-40  
 sickle cell trait and, 12:128-131  
 sodium levels in, 11:464-470, 560, 568-570  
 tests for, 10:122-123  
 agglutination inhibition, 10:305-307  
   Aschheim-Zondek, 10:303, 304  
   biologic, 10:303, 304  
   combination immunologic-biologic, 10:310, 311  
   comparison of immunoassay and bioassay, 10:309-310  
   Gravidex test, 10:306-307, 308, 310, 320-321  
   immunologic, 10:122-123, 305-311  
   positive, and necrotic choriocarcinoma, 10:276  
   quantitative methods, biologic, 10:303-305  
   toad test, 10:303, 304  
 thalassemia and, 12:26, 115-121  
 thiazide diuretics in, 11:570-576  
 thromboembolic disease in, 11:290-309  
 thrombophlebitis in, 11:994-997  
 thyroid changes in, 10:298  
 toxemia in hemoglobinopathies, 12:129-130, 137, 146  
 toxemia of, *see* Toxemia  
 trophoblastic disease and, 10:276, 278-280, 281  
 ultrasonic fetal monitoring in, 11:1154-1164  
 upright posture in, and sodium retention, 11:466, 560  
 ureters in, 11:536-537  
 uric acid secretion in, 11:464  
 urinary 17-hydroxycorticosteroid levels in, 10:90  
 urinary progesterone levels in, 10:47, 48  
 urinary tract infections in, 10:168-169, 175  
 uterine hemodynamics in, 11:69-76  
 uterine rupture in, 12:621-622  
 vulvar cancer and, 10:649-650  
*See also* Delivery; Labor  
 Pregnanediol, 10:383, 698-699  
   excretion determination, 12:898-899  
   levels  
     affecting fetus, 11:1112-1113  
     in menstrual cycle, 12:710, 743, 750  
 Pregnant mare's serum (PMS), 10:401  
 Premarin in dysmenorrhea, 12:715  
 Prematurity  
   bacteriuria and, 11:540-543  
   congenital heart disease in mothers and, 11:1057  
   estriol excretion patterns and, 11:1107-1108  
   in hemoglobinopathies, 12:38, 68, 136, 142, 150, 153-155  
   maternal jaundice and, 11:503  
 Premenstrual tension syndrome, 12:728-735  
 Prenatal patients, cytologic screening of, 12:313-316  
 Pressure  
   blood, *see* Blood pressure  
   intrauterine, 11:35, 40, 41  
 Prilocaine in obstetrics, 12:603  
 Proaccelerin (Factor V) in blood, 11:209  
 Procaine anesthesia, 12:603  
 Proconvertin (Factor VII) in blood, 11:209, 466, 568  
 Progesterone hormones in peripheral plasma, 10:33-34  
 Progesterone, 11:21-23  
   administration, 11:56-58  
   adrenal steroid precursors of, 10:53  
   assay, 10:698

**Volume 10**, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

**Volume 11**, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

**Volume 12**, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- biologic activities, 10:47-52  
 chromatography, 10:699  
 fetal influences on metabolism, 10:52-55  
 interrelationship with gonadotropins, 12:750  
 levels affecting fetus, 11:1112-1113  
 placental metabolism of, 10:55-56, 61-63  
 plasma levels in menstrual cycle, 12:749-750  
 in premature labor, 11:22, 57  
 radioisotopic, in umbilical cord blood, 10:53  
 role in hirsutism, 12:812  
 serum levels  
   in menstrual cycle, 10:376, 383  
   in pregnancy, 10:47, 48  
 Progestogens, 10:373, 375-376; 11:633-634, 646  
   antifertility effect, 11:637-638, 639  
   anti-ovulatory effect, 11:633, 634-635, 639  
   clinical uses, 11:670  
   drug build-up, 11:640  
   endometrial suppression by, 11:635-637, 639  
   estrogen with  
     FSH and, 11:642  
     LH and, 11:642  
     ovulation inhibition and, 11:632  
     sequential therapy, 11:642  
     uterine leiomyomata and, 11:654-655  
   intramuscular administration, 11:628-629  
   optimal contraceptive dose, 11:638-640  
   oral administration, 11:628  
   for postpartum psychoses, 11:691  
 Prolactin  
   inhibiting factor, 10:113-114  
   *See also* Luteotropic hormone  
 Promethazine, action of, 12:596  
 Propion gel in candidiasis, 12:209  
 Prosthetic heart valves in pregnant patients, 11:1018-1019  
 Protein  
   in amniotic fluid, 11:1199-1200  
   fetal metabolism of, 11:1191-1192  
   immunologic, in fetus, 11:1192  
   synthesis, inhibitors of, 10:24-26  
*Proteus* bacilli, urinary tract infection from, 10:167, 172  
 Prothrombin, 11:209, 213-214  
 Pruritus vulvae, 12:199-200  
 Pseudocyesis, 12:796  
 Pseudohermaphroditism, male, 12:696  
*Pseudomonas*, urinary tract infection with, 10:168, 172  
   antibacterial drug therapy, 10:178  
 Pseudomyxoma peritonei, 10:544-555  
   case studies of, 12:955-957  
 Pseudoprecocious puberty  
   female isosexual, 11:795-812  
   heterosexual, 11:815-832  
 Psychogenic factors in infertility, 12:902-907  
   treatment of, 12:919-920  
 Psychologic analgesia in pregnant cardiac patients, 11:958  
 Psychologic effects of pregnancy, labor and anesthesia, 11:913-914, 946, 1021  
 Psychoedatives for analgesia, 12:595-596  
 Psychosis, menstrual, 12:733-735  
 Psychosomatics  
   of amenorrhea, 12:700, 737-738, 793-794  
   of dysmenorrhea, 12:712, 735-737  
   of hirsutism, 12:803  
   of menstrual disorders, 12:712, 724-736  
   of premenstrual syndrome, 12:728-732  
 Psychotherapy for elderly female, 10:539  
 Pubarche, 11:761-762, 775  
 Puberty, 11:769-778  
   adrenal gland and, 11:774  
   breast development in, 11:761, 775, 796-797, 855  
   central nervous system and, 11:784  
   classification of sexual maturity, 11:854-859  
   growth in, 11:775, 777, 796, 855  
   late development of, 11:759  
   mechanisms of, 11:783  
   neuroendocrine mechanism in, 11:770-772, 796, 855-859  
   normal progression of, 11:775-777, 796-798, 855  
   onset of, 12:694  
     factors modifying, 11:796-770  
   ovarian function and, 11:774, 796  
   pineal gland and, 11:772  
   pituitary gland and, 11:772-773, 796, 856-859  
   precocious, *see* Precocious puberty  
   primary amenorrhea and, 11:854-877  
   pseudoprecocious, 11:795-812, 815-832  
   secondary sex hairs, growth of, 11:761-762, 775, 796-797

- thyroid gland and, 11:773-774  
*See also* Menarche
- Pulmonary changes in pregnancy, 11:975-976  
*See also* Lungs
- Pulmonic stenosis in pregnant patients, 11:1052-1053
- Pulmonic systolic murmur in pregnancy, 11:970
- Pulse rate in pregnancy, 11:1011
- Pyelogram  
 intravenous, in pregnancy, 11:522, 536-537; 12:423  
 retrograde, in ectopic ureter, 10:150, 151, 152
- Pyelonephritis  
 in aged female, 10:523-525  
 in hemoglobinopathies, in pregnancy, 12:34, 130, 138  
 in pregnancy, 11:476, 481, 483, 531, 535, 538-539, 545-546  
 pregnancy following, 11:581-583  
 uremia from, 10:174
- Pyruvate in fetal blood, 11:1189
- Pyuria in urinary tract infections, 10:173
- Quartz rod endoscopy, 12:533
- Quinidine, in mitral stenosis in pregnancy, 11:1021-1022
- Radiation therapy  
 in adenocarcinoma, 10:962-963  
 assessing response to, 12:337-344  
 in cervical cancer, 10:567-581, 593  
 dosimetry, 10:974-1002  
 megavolt therapy, 10:958-962  
 pelvic lymphnodectomy and, 10:965-973  
 results of, 10:958-964  
 chemotherapy with, in cancer, 11:343, 387, 390  
 complications, 10:963-972  
 lymphnodectomy after, 10:965-972  
 megavoltage, 10:958-962  
 in ovarian carcinoma, 11:365, 337; 12:990-991  
 cobalt-60 moving strip technique, 12:994-997  
 histology, 12:993-994  
 management and results, 12:997-1001  
 in postpartum period, 10:963  
 in pregnancy, 10:963  
 in vaginal carcinoma, 10:660-662  
 Radiation reaction, lymphography in, 12:337-344  
 Radioactive decay, 12:399  
 Radiography of pelvis after lymphography, 12:382-384  
 Radioimmunoassay  
 for HCG, 10:126, 127, 311  
 for HFSH, 10:129  
 for HLH, 10:127  
 for HPL, 10:134-135  
 for human gonadotropins, 10:122, 672, 695  
 for insulin, 10:694  
 Radioisotope studies, 12:398  
 agents used in, 12:403-404  
 in bone scans, 12:410-412  
 in brain scans, 12:415  
 in liver scans, 12:405-407  
 in lung scans, 12:414-415  
 in anemia diagnosis, 12:420  
 in blood volume studies, 12:419-420  
 bone scans, 12:410-412  
 brain scans, 12:415-417  
 cardiac pool scanning, 12:417-419  
 hematologic applications of, 12:419-420  
 liver scans, 12:404-409  
 lung scans, 12:412-415  
 methods in diagnosis, 12:402-403  
 physical characteristics of isotopes, 12:399-402  
 principles in, 12:398-403  
 radioactive decay in, 12:399  
 renograms with, 12:424-427  
 safety measures with, 12:420-421  
 tracer material for, 12:403  
 types of scans, 12:402  
 units of measurement, 12:400-402  
 Radiology, *see* Radiation therapy  
 Radiopharmaceuticals, 12:403-404  
 Radiosensitivity testing, 12:335-352  
 choice of therapy and, 12:335-337, 350-351  
 cure rate and, 12:348-349

**Volume 10**, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

**Volume 11**, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

**Volume 12**, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- cytologic studies of tissues in, 12:340-344
- histologic studies of tissues in, 12:337-340
- interpretation of response, 12:345-346
- lymphatic invasion by tumor and, 12:349-350
- results of, 12:347-349
- sensitization response in, 12:341-342
- technique of, 12:344-346
- tumor-cell types, 12:343-344
- tumor virulence and, 12:349-350
- Rapid Cell Spectrophotometer (RCS), 12:321-322
- Record keeping
  - in cytologic screening, 12:326-330
  - in endoscopy, 12:545
- Recruitment of women for cytologic screening, 12:313-318
- Rectocele
  - in elderly patients, 10:488, 495
  - after radiotherapy, 10:588
- Rectosigmoid reservoir for urinary diversion, 10:221-225
- Rectum, prolapse of, dissection in hysterectomy, 10:930
- Reflector devices for endoscopes, 12:466-469
- Relaxin, uterine effect, 11:55
- Renin
  - plasma levels in normal pregnancy, 10:94
  - plasma levels in toxemic pregnancy, 10:96-97
  - in primary aldosteronism, suppressed activity of, 10:100
- Renogram, radioisotope, 12:424-427
- Reproduction, explained to adolescent, 11:763-764
- Reproductive biology, endoscopic, studies of, 12:547-549
- Reproductive tract, in aging female, 10:454-465
- Respiration in pregnancy, 11:941-943
  - and placental gas transfer, 11:1165-1179
- Respiratory system in pregnancy, 11:975-976
- Retrodisplacement of uterus, dysmenorrhea in, 12:721-722
- Retroperitoneal fibrosis, idiopathic, 10:175, 214, 239, 248
- Rheology Test, 12:885, 899-900
- Rheumatic heart disease in pregnancy, 11:1010-1025
  - anemia with, 11:1020
  - anesthesia in, 11:962-963
  - antibiotic prophylaxis, 11:1019-1020
  - bacteremia in, 11:1023
  - digitalis in, 11:1021-1022
  - interruption of pregnancy and, 11:1017
  - labor and delivery in, 11:1023-1024
  - management of, 11:1016-1024
  - mitral stenosis, 11:1015-1016
  - mitral valvotomy in, 11:916-917, 978-990, 1018, 1041-1046
  - obesity and, 11:1021
  - physical activity in, 11:1020
  - prosthetic heart valves in, 11:1018-1019
  - pulmonary edema and, 11:1023
  - quinidine in, 11:1021-1022
  - and urinary tract infection, 11:1020
- RNA
  - estrogen effect, 10:74
  - inhibitors, 10:24-26
  - relationship with estrogen, 10:677-678
- Rose bengal, iodinated, in liver scanning, 12:405-406
- Rupture of uterus, cesarean hysterectomy in, 12:621-622, 642, 649, 655, 672
- Salpingitis
  - acute, treatment of, 12:230-231
  - medroxyprogesterone acetate in, 12:250
  - recurring, menstruation suppression in, 12:249-251
  - unrecognized, surgery in, 12:274-275
- Salt-losing adrenogenital syndrome, 12:777, 778-779
- Scanning with radioisotopes, *see* Radioisotope studies
- Schiller test and culposcopy, 10:812
- Scintillation crystal probe detector, 10:980-981
- Scopolamine in pregnancy with heart disease, 11:948, 954
- Sedatives in pregnancy with heart disease, 11:948, 954
- Selenite, radioactive, in bone scans, 12:412
- Semen and infertility, 12:853, 855, 859, 861, 864-866, 911-912
- Sensitization response (SR), and radiation response, 12:341-342
- Sepsis, cesarean hysterectomy in, 12:622, 648, 658, 672
- Septal defects, cardiac, in pregnant patients, 11:964, 1052, 1053
- Serum thrombotic accelerator (STA), 11:202-203

## Sex

- attitude toward, 11:686-687
- behavior of elderly female, 10:541-542
- chromosomes, anomalies, and primary amenorrhea, 11:845-849
- determination in CAH, 11:825-826
- education of adolescents, 11:757-767
- steroids, 10:17-38
  - urinary assay of, 10:40-45
- Sexual differentiation of central nervous system, 12:796-797
- Sheehan's syndrome, 12:795-796
- Sickle cell anemia, 12:33-34, 50, 124
  - affecting reproduction, 12:66
  - incidence of, 12:64-65, 125
  - pregnancy and, 12:38-40
  - transfusions in, 12:40
- Sickle cell test, 12:77-80
- Sickle cell trait, 12:29-32, 34, 50, 124-126, 127
  - affecting reproduction, 12:68-70, 125-131
  - capillary obstruction and, 12:32-33
  - hematuria and, 12:127, 138
  - hemolysis and, 12:32, 138
  - kidneys in, 12:34, 127
  - metabisulfite test for, 12:125-126
  - pathophysiology of, 12:126-128
  - pregnancy and, 12:34, 128-131
  - thalassemia and, 12:34-35, 60
  - See also Hemoglobin S
- Smear studies, see Cytologic screening
- Smegma as cervical carcinogen, 10:755-756, 891, 892
- Sodium in pregnancy, 11:568-570
  - dietary, and aldosterone, 11:569-570
  - excretion of, 11:464-467, 569
  - retention of, 11:465-466, 568-570
- Solid state detectors, 10:978-980
- Souffle, mammary, in pregnancy, 11:973-974
- Sparteine sulfate effect on labor, 11:45, 46
- Speck test, 12:896
- Spectrophotometer, rapid cell, 12:321-322
- Spinal anesthesia, 12:604-606
- Spinnbarkeit, 12:885
- Spleen in hemoglobinopathies, 12:28-29, 82, 126-127, 150
- Squamous cell carcinoma, 11:369
  - chemotherapy of, 11:367-380
  - original treatment of, 11:375-376
- Staging in ovarian carcinoma, 12:935, 937-941
- Staphylococci in pelvic infections, 12:226
- Staphylococcus urinary tract infections, 10:168, 172
  - antibacterial drug therapy, 10:179-180
- Starch test, 12:896
- Stein-Leventhal syndrome, 12:702, 790-791
  - 17-ketosteroid excretion in, 12:780
- Stenosis
  - cervical, and dysmenorrhea, 12:710-711, 722
  - mitral, in pregnancy, 11:1015-1016
  - pulmonic, in pregnancy, 11:1052-1053
- Sterility, see Infertility
- Sterilization
  - in cardiac patients, 11:1061
  - cesarean hysterectomy for, 12:587-588, 642, 649, 655, 677
  - in hemoglobinopathies, 12:119, 140, 149
  - tubal ligation for, 12:652, 681-684
- Steroid therapy and breast cancer, 11:401-404
- Steroidogenesis in ovarian tumors, 12:934-935, 1018-1020
  - tests for abnormalities
    - dexamethasone and HCG test, 12:1021-1022
    - Metopirone test, 12:1020-1021
    - pituitary gonadotropin suppression test, 12:1022-1024
  - procedures, 12:1020
- Steroids
  - for therapy in dysmenorrhea, 12:714-716
  - See also Corticosteroids
- Still's murmur in pregnancy, 11:971
- Stomach contents, aspiration of, in anesthesia, 11:1002-1008
- Storer cesarean hysterectomy, 12:576
- Streptococci in pelvic infections, 12:227

**Volume 10**, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

**Volume 11**, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

**Volume 12**, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- Streptococcal urinary tract infection,  
10:168, 172
- Streptomycin in pelvic infections,  
12:222-233, 280
- Strontium, radioactive, in bone scans,  
12:410
- Stuart-Power factor (Factor X),  
11:210, 212-213, 218
- Succinylcholine, effects of, 12:602
- Sulfonamides in urinary tract infection,  
10:177, 198
- Supine hypotensive syndrome in pregnancy, 11:932-933, 944
- Supraclavicular arterial murmur in pregnancy, 11:972
- Surgery  
  anesthesia in, *see* Anesthesia  
  in cervical cancer, 10:575, 591-593, 911-957  
    in early cancer, 10:911-939  
    extended radical, 10:940-956  
    hysterectomy, 10:935-938  
    pelvic lymphnodectomy, 10:965-973  
  in culdoscopy, 12:504-507  
  in dysmenorrhea, 12:716-718  
  exenteration procedures, 10:940-941  
  in hirsutism, 12:820  
  hysterectomy, *see* Hysterectomy  
  in laparoscopy, 12:524-525  
  in ovarian cancer, 12:980-991  
  pelvic, radical, 10:945-949  
  postoperative care, 10:955-956  
  postoperative pelvic infections, 12:265-281  
  in pregnant cardiac patients, 11:915-918, 1060-1061  
  anesthesia for, 11:920-921, 940-966  
  emergency cases, 11:1041-1046  
  extracorporeal circulation in, 11:917-918  
  mitral valvulotomy, 11:916-917, 978-990, 1018, 1041-1046  
  pregnancies after, 11:985-986, 1051, 1060  
  results of, 11:1051  
  preoperative care, 10:950-951  
  in thromboembolic disease, 11:245-248, 275-276  
  in tubo-ovarian abscess, 12:256
- Systolic murmurs, in pregnancy, 11:970
- Tachycardia, paroxysmal atrial, in pregnancy, 11:921
- Taxonomic Intracellular Analytic System (TICAS), 12:320-321
- Technetium pertechnetate in brain scanning, 12:415
- Television  
  with culdoscopy, 12:512  
  with endoscopy, 12:472-474, 541-544
- Testes  
  choriocarcinoma of, HPL levels in, 10:138  
  endocrine function during intra-uterine life, 10:54-55  
  feminization, testicular, 11:840-844, 12:696
- Testicular biopsy and infertility, 12:866-867
- Testosterone  
  assays of, 12:813-815  
  levels in hirsutism, 12:803-809  
  metabolism of, 12:804-807  
  in peripheral plasma, 10:30-33  
  placental perfusion of, 10:62  
  production rates, 12:815-816  
  in urine, 10:41-44
- Tetracaine in spinal anesthesia, 12:604
- Tetracyclines in pelvic infections, 12:221-222, 280
- Thalassemias, 12:23-28, 58-63  
  alpha, 12:26-28, 29, 61-63, 115  
    Bart's hemoglobin, 12:26-27, 29, 61-62, 115, 119  
    hemoglobin E and, 12:62  
    heterozygous, 12:27-28, 62, 119  
    homozygous, 12:26-27, 119  
    in pregnancy, 12:119-121  
  beta, 12:23-24, 59-61, 115  
    African type, 12:60  
    fertility and, 12:115  
    heterozygous, 12:25-26, 60  
    homozygous, 12:24-25, 60  
    Mediterranean type, 12:60  
    pregnancy and, 12:26, 115-119  
  clinical classification, 12:58-59  
  genetic loci in, 12:20  
  intermedia, 12:24, 59  
  major, 12:23, 58  
  minima, 12:24, 59  
  minor, 12:24, 58  
  sickle-thalassemia, 12:34-35, 60
- Theca-cell tumors and pseudoprecocious puberty, 11:806-807
- Thelarche, 11:775
- Thiazide diuretics in pregnancy, 11:570-576  
  in acute renal failure, 11:564-565  
  maternal and fetal hazards of, 11:572-574  
  prophylactic use of, 11:574-575

- Thimble ionization chambers, 10:977-978
- Thiotepa therapy in ovarian cancer, 11:346, 355, 428-436  
as adjunct to surgery and radiotherapy, 11:430-432  
intracavity application, 11:429-430
- Thrombin, 11:199, 207, 214-215
- Thrombocytopenia, 11:225  
cancer chemotherapy and, 11:348  
neonatal, 11:573
- Thromboembolic disease  
antibiotic therapy, 11:271  
anticoagulants in, *see* Anticoagulants  
computer analysis of, 11:245  
diagnosis, 11:248-254, 265-269  
etiology, 11:198-199  
experimental thrombosis, 11:197-205  
after HPFSH therapy, 10:414  
incidence, 11:197-198  
local trauma and, 11:260  
oral contraceptives and, 11:675-677, 701-710, 725-727  
ovarian, 11:252-253  
pathophysiology, 11:291-292  
peripheral, 11:266-267  
postoperative complications, 11:257-278  
in pregnancy, 11:290-309  
prevention of, 11:236-248, 263-265  
pulmonary embolism in pregnancy, 11:307-309, 993  
surgery for, 11:245-248, 275-276  
symptoms of, 11:249-250  
thrombotic process, 11:259-260  
291-292  
use of I<sup>125</sup>, 11:253-254  
venous, in elderly surgical patient, 10:485-486  
venous stasis and, 11:260-261
- Thrombophlebitis  
in pregnancy, 11:994-997  
septic pelvic, 12:231, 240-245
- Thrombus formation, 11:198, 200-203
- Thyroid gland  
carcinoma of, 10:470  
diseases in elderly surgical patient, 10:484-485  
function with hydatid mole, 10:296-298  
function tests, 12:762-768  
menstrual disorders in disease of, 12:755-768  
in old age, 10:469-470  
puberty and, 11:773-774, 876-877
- Thyroid stimulating hormone  
with hydatid mole, 10:296  
with metastatic choriocarcinoma, 10:296-298
- Tissue thromboplastin (Factor III), 11:208, 209, 215-216
- Toluidine blue test, and CIN, 10:763
- Toxemia of pregnancy, *see also* Eclampsia; Preeclampsia  
adrenal function in, 10:94-95  
bacteriuria in, asymptomatic, 10:174-175  
folic acid deficiency and, 11:1149  
in hemoglobinopathies, 12:129-130, 137, 146  
hepatic lesion in, 11:493, 496  
hydatidiform mole and, 11:483  
liver biopsy in, 11:496-501  
liver failure and, death from, 11:502  
physiologic alterations in, 11:492-493  
pyelonephritis and, 11:481, 483  
renal biopsy in, 11:473-485, 508-516  
renal lesions and, 11:476-477, 479-481, 506-508  
uncomplicated death in, 11:497, 502
- Tracer material for scanning studies, 12:403
- Tranquilizers  
for analgesia, 12:595-596  
uterine effect, 11:64
- Transabdominal intrauterine recording  
method, 11:34, 35
- Transfusions  
in cesarean hysterectomy, 12:644, 669, 680  
in hemoglobinopathies, 12:40, 117, 138, 140, 148
- TRIC organisms in genital tract infections, 12:173-175, 211
- Trichloroethylene anesthesia, 12:594, 599
- Trichomonas vaginalis*, 12:201-204  
oral contraceptives affecting, 12:208  
treatment of, 12:203-204
- Trilene anesthesia, 12:594, 599

**Volume 10**, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

**Volume 11**, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

**Volume 12**, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.



- Trisomies, 12:437
- Trophoblast, histologic interpretation, 10:269-288
- Trophoblastic disease of gestational origin, 10:267-341
- endocrine aspects, 10:290-300
- metastatic, 10:267, 269
- molar pregnancy, 10:313-322
- nonmetastatic, chemotherapy in, 10:323-329
- See also* Choriocarcinoma; Hydatidiform mole
- Tubal ligation, 12:652, 676-687
- complications of, 12:683-684
- incidence of, 12:678
- Tuberculosis
- endometrial cancer and, 10:637-638
- genital, treatment of, 12:233
- pelvic, infertility and, 12:879
- renal, and pregnancy, 11:585
- urinary tract infections and, 10:175
- Tubes, Fallopian, *see* Fallopian tubes
- Tubocurarine for cesarean section, 12:601-602
- Tumor-cell types, characteristics of, 12:343-344
- Tumors
- adrenal, virilizing, 12:779-780
- angiography in, 12:387-394
- assay of virulence of, 12:349-350
- bladder, 10:206, 207
- cervical, *see* Cancer—cervical
- colorectal, 10:555
- cytologic screening for, 12:303-333
- growth mechanisms, 10:904-907
- lymphography in, 12:372-387
- mesenteric, 10:556-557
- metastatic, *see* Metastatic disease
- ovarian, *see* Cancer—ovarian
- pelvic, 10:202-236, 524-525
- pineal, 12:787
- of pouch of Douglas, 10:559
- radiosensitivity testing in, 12:335-352
- rectal, 10:553, 555
- renal, in aged female, 10:524-525
- resistance to chemotherapy, 11:339-340
- sigmoid, 10:552-553
- ultrasonics in, 12:354-370
- urethral, 10:210-212, 230, 234-236, 521
- uterine, secondary, 10:559
- See also* Cancer; Ovaries; Uterus
- Turner's syndrome, 11:847-848
- amenorrhea in, 12:697
- Twins and oxytocinase in maternal plasma, 11:1103-1104
- Ultrasonics
- for evaluation of fetal status, 11:1154-1164
- criteria for adequate system, 11:1157-1158
- with external tocography, 11:1158-1164
- in fetal distress, 11:1162-1163
- limitations of, 11:1155-1157
- in normal pregnancy, 11:1161-1162
- technical description, 11:1159-1161
- with uterine monitoring, 11:1159
- in pelvic cancer, 12:354-370
- abdominal scan, 12:356-357
- characteristics of malignancies, 12:364-365
- clinical applications of, 12:355
- in cystic and solid tumors, 12:358-361
- fluid studies in, 12:361-363
- indications and interpretation, 12:358-369
- in metastatic disease, 12:365-369
- techniques of, 12:356-357
- therapeutic follow-up, 12:369
- tumor echo patterns, 12:369-370
- Umbilical cord
- acid-base balance of, and condition of newborn, 11:168
- compression of, 11:149, 150
- Urachus, tumors of, 10:212, 214
- Urea excretion, 11:487-488
- Uremia from pyelonephritis, 10:174
- Ureter(s)
- dissection in hysterectomy, 10:929-930
- ectopic, 10:147-154, 159, 175
- fistula of, 10:528-530, 548
- injury in cesarean hysterectomy, 12:644, 650, 670-671
- obstruction in gynecologic cancer, 12:428-432
- and pelvic masses, 10:204-206
- See also* Ureterocele
- surgical trauma, 10:204-206
- Ureterectomy, partial, for ectopic ureter, 10:150, 152, 153
- Ureterocele, 10:155-164, 205-206
- bladder distention in, 10:157, 158
- ectopic, 10:155
- prolapsed, 10:157, 162, 163, 205
- renal damage with, 10:163-164
- simple, 10:155, 156
- stone-bearing, 10:163
- symptoms, 10:156-157
- transurethral incision of, 10:163



- treatment, 10:162-164, 206  
 ureteral duplication with, 10:159, 161-162  
 vesical irritation and obstruction with, 10:156-157  
 Ureterosigmoidostomy, 10:217-221  
 Ureterovaginal fistula, 10:528-530, 548  
 Urethane therapy in pregnancy, 11:423  
 Urethra  
   bacteria entering bladder from, 10:195  
   benign masses of, 10:212  
   cancer of, 10:230, 521  
   caruncle, 10:228-231, 521  
   cleansing of, to avoid infection, 10:195  
   condylomata acuminata of, 10:233  
   congenital defects of, 10:227-228  
   cysts, 10:233-234  
   diverticulum, 10:212, 213, 521  
   endometriosis of, 10:233  
   foreign bodies in, 10:212  
   hypospadias, 10:228  
   lesions, 10:227-236  
   mucosal prolapse, 10:229  
   polyps, 10:229, 231  
   trauma, 10:232-234  
   tumors, 10:210-212, 230, 234-236, 521  
 Uric acid, 11:464, 489, 493  
 Urinary incontinence  
   in elderly female, 10:519-520  
   evaluation of, 10:519-520  
   overflow, 10:519, 520  
   severe urgency, 10:519, 520  
   stress, 10:519, 520  
   after surgical repair of cystocele, 10:490-491  
   total, 10:519, 520  
   ureteral ectopy with, 10:147-152  
 Urinary tract  
   infections of, 10:166-182, 203, 485, 522-525  
     hemoglobinopathies, 12:34, 130, 138, 139, 146, 155  
   in pregnancy, 11:533-547  
   in pregnancy with heart disease, 11:1020  
   subsequent pregnancies, 11:580-583  
   injuries from surgery, 10:526-530  
 Urine  
   collection of specimen, 10:170-171  
     midstream specimen, 11:534  
   culture, 10:170, 171, 552  
   diversion of, in interstitial cystitis, 10:190  
   estriol in, in pregnancy, 11:1106-1109  
   excretion rate, 11:550  
   ovulatory changes in, 10:386  
   progesterone in, in pregnancy, 10:47  
   red cells in, 11:535, 599  
   sex steroids in, 10:40  
 Urobilinogen excretion, 11:489  
 Urocytogram, uses of, 11:1125  
 Urography  
   excretory, in ectopic ureter, 10:148, 149, 151  
   intravenous, 11:474-475  
 Urologic evaluation, 12:853  
 Urologic studies in gynecologic cancer, 12:423-432  
 Uteroplacental circulation, 11:71-72  
   arteries in, 11:79-83  
   in labor, 11:93-94  
   mechanism of, 11:83, 86-93  
   veins in, 11:83, 85  
 Uterosalingography, 12:893-896  
 Uterus  
   afferent nerve impulses from, 11:19-20  
   in aged, 10:460-461  
   blood flow in, 11:69-76, 96-108  
   calcium deprivation affecting, 11:23  
   cancer of, *see* Cancer—uterine  
   cervical conditions, *see* Cervix uteri  
   contraceptive device, intrauterine, 11:627, 685; 12:179-195  
   contractility of, 11:13  
   cardiac output and, 11:934-935  
   FHR and, 11:146-158  
   in labor, 11:99-104  
   in late pregnancy, 11:36-37  
   nervous control of, 11:15-31  
   puerperal changes, 11:125-144  
   disorders with dysmenorrhea, 12:710-711, 721-722  
   electrical impulses affecting, 11:20-24

Volume 10, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

Volume 11, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

Volume 12, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.

- fibroids of, and adenocarcinoma, 10:630-631
- hemodynamics in pregnancy, 11:69-76
- herpetic cervicitis, 12:164
- hormone release in, nervous control of, 11:24
- infertility and, 12:859, 879
- innervation of, 11:16-19
- malignancies of
  - angiography in, 12:391-393
  - chromosomes in, 12:441-445
  - cytologic studies in, 12:305-307, 310-311
  - lymphography in, *see* Lymphography
  - urologic studies in, 12:428-432
- monoamines in, cellular distribution of, 11:17
- nonpregnant, 11:15, 24, 26
- normal adult weight of, 10:460
- oral contraceptives affecting, 11:654-660
- ovarian hormones affecting, 11:55-58
- perforation of, and endometrial cancer, 10:635
- perfusion pressure, 11:97
- peritonization of cervical stump, 12:583
- in pregnancy and labor, 11:26-27, 71-72
- pressures in, 11:35, 40, 41
- progesterone affecting, 11:21-23
- prolapse of, 10:488, 491-492
- psychogenic bleeding in, 12:737
- relationship to vagina, 10:858
- relaxants affecting, 11:50-55
- secondary tumors of, 10:599
- size during pregnancy, 11:15
- TRIC agent infections of cervix, 12:173-174
- See also* Hysterectomy; Myometrium
- Vaccinia of vulva, 12:168-169
- Vagina
  - in aged, 10:459
  - cancer of, 10:655-663
  - congenital absence of, 11:851
  - cytology of, *see* Cytology
  - foreign bodies in, 12:212
  - hysterectomy through, 12:583
  - infection after, 12:269, 275
  - imperforate and primary amenorrhea, 11:844-845
  - infertility and, 12:879-880
  - dyspareunia, 12:881
  - inflammation, 12:880-881
  - obstruction, 12:880
  - treatment, 12:913
  - nodule of, 10:280-281
  - oral contraceptives affecting, 11:660-661
  - pH changes during ovulation, 10:385
  - preoperative preparation of, 12:271
  - relationship to uterus, 10:858
  - tumors, malignant, 10:655-663
- Vaginal cuff infection, postoperative, 12:275-277
- Vaginitis
  - atrophic, 12:213-215
  - Candida albicans*, 12:204-210
  - Hemophilus vaginalis*, 12:210
  - nonspecific, 12:213-215
  - senile, 12:213-215
  - Trichomonas vaginalis*, 12:201-204, 208
  - viral, 12:211
- See also* Vulvovaginitis
- Valvulotomy, mitral, in pregnancy, 11:916-917, 978-990, 1018, 1041-1046
- Varicella and herpes zoster, 12:167
- Varicose veins in pregnancy, 11:975
- Vascular conditions
  - hypertensive disease, *see* Hypertension
  - peripheral system, in pregnancy, 11:974-975
  - pressures in, *see* Blood pressure
  - uterine blood vessels, 11:23-24
- Vasokonstriction of spiral vessels and dysmenorrhea, 12:711
- Veins
  - air embolism in pregnancy, 11:997
  - changes in pregnancy, 11:975
  - ligation in pregnancy, 11:996-997
  - stasis of, and thromboembolic disease, 11:260-261
  - thromboembolism in elderly surgical patient, 10:485-486
  - varicose, in pregnancy, 11:975
- Venography, *see* Angiography
- Venous hum in pregnancy, 11:972-973
- Ventilation, pulmonary, in pregnancy, 11:941-976
- Ventricles, cardiac
  - left, work in pregnancy, 11:929
  - right, changes in pregnancy, 11:928, 933-934
  - septal defect in pregnant patients, 11:1053-1054
- Verruca vulgaris, genital, 12:170-172
- Vesicoureteral reflux, 10:153, 163
- urinary tract infections with, 10:168
- Vesicovaginal fistula, 10:527, 548, 935-936


- vaginal carcinoma and, 10:662  
Vinblastine therapy in pregnancy, 11:422  
Viral infections of genital tract, 12:161-177  
    adenovirus infection, 12:170  
    *Bedsonia* agents, 12:161, 173, 175  
    condyloma acuminatum, 12:170-172  
    cytomegalovirus infection, cervical, 12:169-170  
    lymphogranuloma venereum, 12:175-176  
    molluscum contagiosum, 12:172-173  
    TRIC organisms, 12:173-175, 211  
Virilization in adrenal hyperplasia, 11:815-816; 12:774-780  
Virulence of tumors, assay of, 12:349-350  
Vomiting, with anesthesia, 12:614-615  
Von Willebrand's disease, 11:225-226  
Vulva  
    atrophy, 10:456  
    basal cell carcinoma, 10:644  
    Bowen's disease, 10:643-644, 645  
    cancer of, *see* Cancer—vulvar  
    herpetic vulvitis, 12:164  
    itching of, 12:199-200  
    kraurosis vulvae, 10:456-457  
    leukoplakia, 10:458-459, 508  
    Paget's disease, 10:644  
    ulcus vulvae acutum (Lipschütz ulcer), 12:166  
    vaccinia of, 12:168-169  
Vulvovaginitis  
    acute, 12:216  
    causes of, 12:198  
    chronic, 12:217  
    gonococcal, 12:211  
    treatment of, 12:215-217  
Water transfer, transplacental, 11:1189  
Warts, *see* Condylomata acuminata  
Weight changes and oral contraceptives, 11:723-724  
Wound infections, treatment of, 12:233-234  
X-rays, therapy with, *see* Radiation therapy  
Xylocaine in obstetrics, 12:603

---

Volume 10, pages 1-256, March issue; pages 257-430, June; pages 431-732, September; pages 733-1052, December.

Volume 11, pages 1-318, March issue; pages 321-616, June; pages 617-894, September; pages 895-1245, December.

Volume 12, pages 1-288, March issue; pages 289-560, June; pages 561-840, September; pages 841-1096, December.



## Notes

## Notes

